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SUMMARY
XXI i
Some patients with atopic dermatitis (AD) react abnormally 
to a number of cutaneous viral infections. Herpes simplex, for 
example can become widely disseminated with severe systemic 
symptoms. This susceptibility of AD patients may be due, at 
least in part, to deficient natural killer cell function.
This study investigated the NK cell activity of AD patients 
using a standard four hour chromium release assay with the 
erythroleukaemic cell line K562 as the target cell. The NK cell 
activity of patients with AD was significantly reduced as 
compared with normal age and sex matched controls.
The effect of the length of incubation time of the assay, 
removal of phagocytic/adherent cells and the use of tai'get cells 
other than K$62 on the standard four hour assay were examined. 
Increasing the incubation time from 4 to l8 hours and removing 
phagocytic/adherent cells resulted in an increase in NK cell 
activity, though the difference in response between patients and 
controls was maintained. In contrast the overall NK cell activity 
was reduced when target cells other then K562 were used, although 
the NK cell activity of the controls remained consistently higher 
than the patients.
Atopic dermatitis is a chronic relapsing disorder and to 
determine whether or not NK cell activity fluctuated with disease
XXlll
severity NK cell activity was examined sequentially over a 12 
month, period in a group of patients. An inverse correlation 
was found between disease severity and NK cell activity, ie, the 
more severe the disease the lower the NK cell activity. A strong 
correlation was also confirmed between clinical activity of the 
disease and IgE level.
The reduction in NK cell activity in AD could result from 
either a qualitative abnormality, ie, normal numbers of effector 
cells with abnormal function, or a quantitative abnormality, ie, 
reduced numbers of effector cells. Effector cell numbers were 
counted using two monoclonal antibodies, HNK-1 (Leu-7) and Leu-11, 
Numbers were then correlated with function, as measured by 
chromium release. Using lINK-1 it appeared there was a reduction 
in the numbers of effector cells and this correlated with the 
reduced activity, HNK—1 does not however, stain all NK effector
cells. Using Leu-llb, which is a more specific reagent, showed 
normal numbers of effector cells are present in the peripheral 
circulation of patients as compared with controls. The reduced 
NK cell activity in atopic dermatitis was therefore thought to be 
due to a functional abnormality in the effector cell's lytic 
cycle.
The reduction of NK cell activity could be caused by 
inhibitors in the serum of patients with AD, This was
XXIV
investigated by incubating effector cells from both AD patients, 
and normal controls in medium supplemented with either serum from 
patients with AD, normal controls or foetal calf serum (PCS),
The NK cell activity was estimated following either a normal 
four hour assay, an extended l8 hour assay or a standard four hour 
assay following an l8 hour preincubation in the supplemented 
media. Using these three protocols no significant increase was 
observed in the patients' effector cell activity following 
incubation in medium supplemented with control serum nor was 
there a significant decrease in control effector cell activity 
following incubation in medium supplemented with patients' serum.
A significant increase in NK cell activity however, was observed 
when either patients' or control effector cells were preincubated 
in medium supplemented with PCS prior to being assayed and was 
most likely due to the mitogenic properties of PCS.
The inverse correlation of disease severity with NK cell 
activity could be due to either the disorder itself or to its 
treatment. The mainstay of treatment in AD is topioal steroids. 
The effect of the application of topical steroids on NK cell 
activity was therefore studied in ten normal volunteers.
Pollowing the application of betamethasone valerate for seven 
nights the NK cell activity of the volunteers was found to be 
reduced. This reduction was first observed on day 3 and reached 
its lowest level on day 8 and then gradually returned to normal
xx;v
about day l8 to 22, Although the fail in NK cell activity seen 
in the normal volunteers was less then that observed in AD this 
may be a dose effect as smaller amounts of steroid would be 
expected to be absorbed through the intact skin of a normal 
control than through the skin of a patient with AD.
Stress is well recognised as one factor which may cause a 
flare in AD. As stress is mediated physiologically by 
adrenaline k noradrenaline the pharmacological effects of these 
agents on the activity of NK cells from normal controls was 
therefore studied. Betamethesone and histamine were also studied, 
the former because of the results of the topical steroid experiment 
and the latter because of its role in allergic disorders.
Following a one hour preincubation adrenaline, noradrenaline 
and betamethasone all inhibited NK cell activity in a dose 
dependent manner^ while histamine slightly increased NK cell activity 
in a negative dose dependent manner. If added to the assay at the 
highest concentration without prior preincubation all of the agents 
caused an increased reduction in NK cell activity. A longer 4 
hour preincubation with the highest concentrations of these agents 
resulted in a reduction in the amount of inhibition compared to that 
found with the other two protocols. Histamine was again found to 
enhance the NK cell response. After a four hour incubation, the 
level of enhancement observed was as great as that found following 
a one hour preincubation with histamine at the lowest concentration.
XXVI
In conclusion, the results of this study suggest that reduced 
NK cell activity in AD may he related to the treatment of the 
disease rather than the disease itself.
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chapter one
INTRODUCTION
One of the more exciting discoveries in immunology in recent 
years has been that of natural cellular cytotoxicity. Natural 
killer, or NK, cells were first encountered during investigations 
into the function of T—cells in tumour control. In vivo 
resistance of a host to tumour growth had been mainly attributed 
to T cells specifically sensitised to tumour associated antigens. 
This was shown by adoptive transfer experiments where following 
transfer of cells from a sensitised donor to an unsensitised 
recipient, the recipient became resistant to subsequent challenge 
with the tumour used to sensitise the donor (Glaser, et al. 1978). 
Because of the recognised importance of immune or activated T- 
cells in the control of tumour growth it was anticipated that 
animals deficient of T-cells, eg. nude mice, would lack resistance 
üO both spontaneous and induced tujnours and the incidence of 
rapidly progressive malignancies in these animals would be much 
higher than in animals with competent T-cell immunity. However, no 
such excess was found in nude mice. Also, patients with immuno­
deficiency disorders were found not to have a wide spectrum of 
malignant disease, as might have been expected. These findings 
coupled with the observation that lymphoid cells from some normal 
mice, rats and human donors, which had not been immunised with 
tumour cells or other sources of alloantigen, had significant 
levels of cytotoxic reactivity against certain syngeneic or 
allogeneic tumours (Herberman, et al, 1973: Nunn, et al. 1978;
Rosenberg, et al. 1974), led to the discovery of natural cell
mediated cytotoxicity. Up to this time cell mediated cytotoxicity 
against tumour cells had been thought to he mediated hy three types 
of effector cell, these were:- (i) specifically immune T-cells,
(ii) antibody dependent cytotoxic cells, which depend upon IgG hound 
to the target cell (also known as K cells), and (iii) activated 
macrophages or macrophages armed with specific antibodies (Cerottini 
and Brunner, 1974)*
Definition of natural cytotoxicity.
Spontaneous cytolysis hy a discrete lymphoid suhpopulation 
was first recognised in 197S during studies designed to identify 
immune cytotoxic T-cells in humans or experimental animals with 
tumours (Pross and Jondal. 19754 Herberman, et al. 1975). Normal 
individuals were found to possess lymphocytes with the ability to 
recognise and kill rapidly (within hours) a variety of tumour and 
virus infected cells in vitro. These effector cells have become 
known as natural killer, or NK cells.
Natural cytotoxicity or killing may therefore be described as 
cytotoxicity, observed in vitro, excerted against a variety of 
tumour or virus infected cells by a discrete lymphoid subpopulation 
of mononuclear cells with the characteristics of LGL, from apparently 
normal unimmunised donors without the addition of external antibodies 
or deliberate in vitro activation of the effector cells.
Morpholog'iça.l characteristics of NK cells.
In humans it has been shown that NK cell activity lies 
within a discrete subpopulation of non-B, non—T, non-adherent 
and non-phagocytic lymphocytes which lack demonstrable surface 
immunoglobulin and with a different morphology from typical 
lymphocytes (Timonen, et al. 197.9: Peter, et al. 1975: Santoli, 
et al. 1978). NK cells have been described as large granular 
lymphocytes (LGL) because of their unique morphology. LGL have 
a pale cytoplasm, slightly eccentric reniform nucleus, a high 
cytoplasmic: nuclear ratio azuxppKilic granules in the cyto­
plasm and are larger than normal lymphocytes (see plate one),
LGL have been shown to be the effector cells for NK activity as 
it has proved impossible to separate LGL from cytolytic function 
by either adherence to lai'get cells or sedimentaiioii per coll 
density gradients (Timonen, et al. 198I: Timonen and Saksela, 
1980), In addition^lymphocyte populations enriched for LGL, 
show a greater level of natural cytotoxicity than do normal 
cell populations which in turn have a greater level of cyto­
toxicity than do lymphocyte populations depleted of LGL.
Origin of NK cells.
NK cells cire derived from bone marrow stem cells. This has 
been shown by repopulating radiation chimeras with small numbers 
of bone marrow cells (Haller, et al. 1977)* Further evidence 
which supports a bone marrow origin for the stem cell has come
Plate one.
i  i
i
= :^.
Large granular lymphocyte, stained with May-Grunwald Giemsa, 
magnification x1,000, Bar represents 20pm.
Ua
from the observation that NK function is markedly suppressed in 
osteopetrotio mice, or mice treated with the bone seeking isotope 
^^Sr. (Seaman, et al. 1979: Haller and Wigzell 1977).
Size of population and distribution.
NK cells or LGL represent a small subpopulation of lymphocytes 
in the blood or spleen. About of circulating mononuclear 
cells have the characteristics of LGL, and up to 75^ of these 
have been shown to be able to function as NK cells (Timonen, 
et al. 1981).
NK cells can be found in the foetal liver of man and are 
functionally active around the ninth week of gestation (Timonen, 
ex ai. I98I: llkoila, et al. I9B3). At birth they are prcsenx
in significant numbers in cord blood (Forbes, et al. I981) though 
they are not as active as those found in the peripheral blood 
of adults. NK cell activity can be found through the body to 
various degrees; the highest levels being found in the peri­
pheral blood and spleen with low levels in bone mai^ row, lymph 
node and thoracic duct and no detectable activity in the thymus 
(Antonelli, et al. I98I).
Mechanism of action of NK cells.
The mechanisms by which NK cells recognise,interact and
finally destroy susceptible target cells remain controversial, 
however, four separate steps can be identified during the killing 
of target cells. These are:—
i) recognition and binding of effector cells to the 
target cells.
ii) Triggering and activation of the lytic cycle.
iii) Release of the lytic agent,
iv) Target cell death and recycling of the effector 
cell.
i) Target cell recognition and binding.
The chemical nature of the structures on the target cell 
recognised by receptors on the NK cell is unknown, although a 
number of theories exist.
Both glycoproteins and glycolipids have been suggested 
(Roder, et al. 1979: Roder, et al. 1979: Young et al, I981).
The capacity of some simple sugars to inhibit NK cell cytotoxicity
has been cited as evidence for a lectin—ligand like interaction 
in effector cell/target cell binding (Stutman, et al, I98O: 
MacDermott et al. I981), It has been demonstrated recently 
however, that such sugars may exert their inhibitory influence 
at a post-recognition stage in the lytic cycle (Vose, et al. I983). 
Effector cell recognition may also be influencedby the degree of
target cell sialylation, ie. the more sialic acid there is present 
on the target cell membrane, the less efficient the effector cell 
binding and therefore the more resistant the target cell will be 
to NH cell mediated lysis (Yogeeswaran, et al. I98I; Werkmeister, 
et al. 1983).
More recently the transferrin receptor has come under scrutiny. 
One study suggested that NK cell interaction with K^ 62 target cells 
is mediated through the recognition by effector-borne transferrin of 
transferrin receptors expressed by the target cell (Vodinelich, et al. 
1983: Baines, et al. I983)# Another study however, found contradictory 
evidence showing that neither apo-transferrin nor iron saturated 
transferrin caused a significant inhibition of lysis (Werkmeister,
et al. 1983).
From the results of "cold competition" analysis, in which 
the capacity of unlabelled cells to compete with chromium 51 
labelled cells for lysis by NK cells is measured, it would appear 
that both common and non crossreactive recognition structures 
exist which are expressed by different target cell populations 
(Ortaldo, et al. 1977: Gallewaert, et al. 1979)* NK cells reactive 
with recognition structures expressed by a target cell may be specific­
ally removed from the effector population by absorption onto target 
cell monolayers (Jensen and Koven, 1979). Depletion of an effector 
population by this method does not prevent lysis of a different 
target cell type (Phillips et al. I98O)
This implies that target receptors of different 
specificities are distributed among NK cell populations. This 
theory is supported by preliminary evidence from the results of 
clonal analysis of both human and murine NK cell populations. 
There exists therefore, at least limited clonal distribution of 
target cell selectivity (Hercend et al. 1983: Kedair, et al.
1982).
The effector cell/target cell binding is most likely to 
involve a receptor—ligand interaction between a structure on the 
surface of the target cell and a receptor on the surface of the 
NK cell. The exact nature of the receptor is not known but in 
the mouse pretreatment of the effector cells with trypsin, papain 
or pronase prevents target sell binding and subsequent
cytolysis (Roder, et al. 1978). Both these functions regenerate 
over a four hour time course. Preincubation for I8 hours with 
inhibitors of protein synthesis also decreases both target cell 
binding and cytolysis. These observations suggest that the 
receptor on the surface of the NK cell is a de-novo synthesised 
protein with a turnover time similar to that of other membrane 
proteins.
Although effector cell recognition of, and binding, to the 
target cell is a prerequisite for lysis it is obvious that this
alone is not enough. Normal cells may he bound by NK cells but 
are not lysed, (Brooks, et al, 1981), and variants of K562, which 
exhibit increased resistance to natural cytotoxicity, have 
identical effector cell binding to their more susceptible counter­
parts (Kimber, et al. I983), It is likely therefore, that the 
sensitivity of a cell to NK lysis is influenced by inherent 
resistance mechanisms which operate at a post recognition stage 
of the lytic cycle. The exact nature of such a mechanism is 
unclear though evidence for both protein synthesis dependent 
(Hudig, et al. I98I: Kunkel and Welsh, I981), and independent
mechanisms (Kimber, et al. 1983) exists,
ii) Triggering and activation of the lytic cycle.
Triggering and activation of the lytic cycle follows target 
cell binding. The cellular events which result in this activation 
and subsequent target cell death are not yet fully understood.
A stimulus-secretion model has been proposed for NK cell 
mediated killing. Pollowing contact with an appropriate target 
cell, the NK cell is triggered to secrete a factor, or factors, 
which then result in the lysis of the target cell (Roder, et al. 
1980). This part of the lytic cycle would appear to be controlled 
by cyclic nucleotides. It has been shown that the induction of 
cyclic AMP by prostaglandins inhibits cytotoxicity (Hall et al. 
1983) whereas cyclic GMP, or its inducers, including interferon,
c&use augmentation of cytotoxicity (Katz, et al. 1982).
iii) Release of the lytic agent.
One of the first measurable events after target cell binding 
is a rapid burst of superoxide anion, 0^ , generation, which can 
be measured in a chemiluminometer (Roder, et al. 1982: Helfand, 
et al. 1982). If Og production is blocked by superoxide 
dismutase an inhibition of NK cell activity results, however,
Og is not thought to be the sole lytic agent. Patients with 
Ghediak-Higashi syndrome have been found to produce normal 
amounts of 0^ but are unable to lyse NK targets (Roder, et al. I983) 
It has been postulated that 0^ may act as a cofactor or activator 
for a later step in the chain of events leading to lysis of the 
target cell.
Another early event in the lytic cycle is the methyl ation of 
phospholipids within the NK cell, along with an increase in 
phospholipase activity (Hoffman, et al. I981). The role of 
enzymes, or their products, however, remains to be established.
It is also possible that the aaurophilic granules in the
cytoplasm of NK cells have an active role in target cell lysis. 
2+Exposure to Sr causes degranulation of LGL, with a subsequent 
reduction in cytotoxicity (Neighbour and Huberrnan, 1982). 
Further evidence that the granule contents may be involved in 
target cell death has come from the observation that purified
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granules from rat LGL are directly cytotoxic for a variety of cell 
types (Henkart, et al. I984).
Treatment of effector cells with monensin, a carhoxylic 
ionophore which compromises cellular secretions, also inhibits 
NK cell mediated lysis (Carpen, et al. I981). Observations that 
a variety of protease inhibitors can compromise NK cell activity 
has indicated a possible role for lysosomal proteases in the 
lethal hit (Hudig, et al. 198I). The exact nature of the event 
and in particular the role of cytotoxic factors awaits further 
clarification.
iv) Recycling of effector cells.
After administering Ihc leihsl hit go the bound target ceil, 
the effector cell disengages and is then free to recycle and bind 
to another target cell. This capacity of effector cells to
recycle allows a small population to be more effective. If NK
cells killed on a one to one basis the effector population would 
have to be much larger than it is. The rate of recycling has been 
shown to vary between individuals although it is fairly constant 
within an individual (Ullberg and Jondal, I981).
Surface markers.
There have been many studies aimed at the identification
and classification of the effector cell by surface markers, A
11
large proportion of human peripheral blood NK cells have been 
shown to bear receptors for gamma globulin although evidence 
exists for cytotoxicity mediated by PcjjR negative cells as well 
(West, et al. 1977: Kay, et al. 1979)* The observation that 
non-rosetting lymphocytes, as well as those forming both high and 
low avidity rosettes with sheep erythrocytes, can exhibit natural 
cell—mediated cytotoxicity suggests that NK cells are not 
necessarily divorced from the T-cell lineage (West, et al. 1977: 
Potter and Moore, 1979)- In addition studies with heterologous 
anti-T cell antisera have provided indirect evidence for the 
possession of some T-lymphocyte markers by human NK cells 
(Kaplan and Gallewaert, 1978). More recent evidence suggests 
that immature NK cells display the 0KT3 marker during development 
in the bone marrow and spleen, and thax the T'3 marker is lost 
when the NK cells reach a more mature stage in the peripheral 
blood (Abo et al. 1983). Other monoclonal antibodies reactive 
with T—cells have also been shown to recognise a proportion of 
human LGL: eg. both the 0KT8, cytotoxic/suppressor marker and
the OKTIO marker, which reacts with early thymocytes, bind to 
approximately 20^ and 60^ of human LGL respectively (Ortaldo, 
et al. 1981). In addition both 0KM1, which identifies polymor­
phonuclear leukocytes, and Mac 1, which reacts with macrophages, 
have been observed to react with NK cells (Ortaldo, et al. I981),
The first monoclonal antibody, specific for NK cells, to be
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described was HNK-1, now known as Leu-7 (Abo and Balch, I981), 
Leu-7 has been shown to be reactive with most, but not all, NK 
cells (Lanier, et al, 1983). Leu-7 also reacts with cells 
expressing the T-cell associated antigens Leu-1, Leu-2 and Leu-4 
(Lanier, et al. I983). Leu-7 has now been superceded by Leu-11 
which is a more specific monoclonal antibody and unlike Leu—7, 
Leu-11 does not react with Leu-1, Leu—3 or Leu-4 positive cells. 
However, cells positive for the Leu-2a antigen have been found 
that also express the Leu-11 marker but the density of the 2a 
marker on Leu-11 positive cells is much lower than that on Leu-7 
positive cells (Lanier, et al. I983). Another potentially useful 
monoclonal antibody to be described recently is B73.1 which 
apparently recognises an epitope expressed on the Pc R of both 
human granulocytes and. LGL, but ic; operationally specific for 
NK cells in lymphocyte populations (Perussia, et al. I983).
As the technique of producing and selecting monoclonal 
antibodies is improved it is likely that a monoclonal antibody 
which is non-crossreactive will be developed. This may resolve 
the question of heterogeneity among human NK cells, ie. is 
,heterogeneity due to the existence of a variety of discrete, 
but related, cell types or do these differences simply reflect 
variation in the level of differentiation within the NK cell 
population.
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Variations in NK cell activity due to age, sex, and disease.
Age.
In mice^ageing has been shown to have an effect on NK cell 
activity (Herberman, et al. 1975)* Mice under three weeks of age 
lack detectable cytotoxic activity, which appears between four to 
five weeks of age, reaches a peak between five to eight weeks, 
and then gradually declines to low levels of NK cell activity 
between six to twelve months of age.
In contrast to the age dependence of NK cell activity in 
mice, age has not been found to have any major effect on human 
NK cell activity (Fernandes and Gupta, I98I: Penschow and MacKay
1980). NK cell activity can be detected in mononuclear cells 
isolated from cord blood at birth (Forbes, et al. I98I:
Antonelli, et al. I981). After birth natural cytotoxic levels 
increase gradually to high levels in adulthood but, unlike mice, 
no dramatic decrease in activity is seen late in life.
Sex.
In human blood it has been found that males have a slightly 
higher level of NK cell activity than females, this difference has 
also been shown in cord blood (Pross and Baines, 1982: Penschow and 
MacKay, I98O: Antonelli, et al. I981). Within an individual 
levels of NK cell activity remain fairly stable; even when tested 
over many years. Individuals may therefore, be categorised as 
having either high of low levels of natural cytotoxicity (Pross and
Baines, 1982).
Disease.
Low NK cell activity has been described in many diseases 
including malignant disorders such as breast cancer (Cunningham 
Bundles, et al. 1981)» melanoma (Hersey, et al. 1978), Leukaemia 
(Linvat, et al. I98O), and other diseases such as 8LE (Karsh, et 
al. 1981), Hashimoto's thyroiditis (Seybold, et al. I98I) and 
multiple sclerosis (Benczur, et al. I980). No correlation however, 
has been found between low NK cell function and susceptibilty to 
disease in any of these disorders.
Mechanisms by which disease may depress NK cell activity 
may envolve one or more component(s) of the NK cell system and 
modulating factors such as interferon and prostaglandins (Koren, 
et al. 1981 : Targen, et al. I98I: Bankhurst, 1982).
NK cell activity can be enhanced by interferon of all types 
(Ortaldo, et al. I983). In mice inducers of interferon such as 
polyinosinicpolycytidilic acid (poly I;C) can also cause an 
increase in NK cell activity (Djeu, et al. 1979). The mechanism 
of action of interferon is unclear although it probably involves 
the induction of NK cell precursors and an augmentation of the 
potential of existing mature effector cells.
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The lymphokine interleukin 2 (IL—2) has recently been shown 
to potentiate NK cell activity in man (Hersey, et al. 1981),
IL—2 is also Jcnown to be an inducer of interferon (Kasahara, et 
al. 1983), therefore, it is not clear whether IL-2 alone is enough 
to augment lysis or whether it acts indirectly through the production 
of interferon (Weigent, et al. 1983).
A number of mediators including the prostaglandins El, S2 
and D2 can cause a depression of NK cell function (Droller, et 
al. 1978) possibly via an increase in intracellular cAMP (Goto 
et al. 1983). There is also evidence for cellular suppression 
of NK cell activity by macrophages, thymocytes and granulocytes 
(jQndel, et al. I983: Nair, et al. I98I: Kay and Smith, I983).
The role of NK cells in vivo.
The original studies which led to the discovery of NK cells 
suggested that they were involved in immunological surveillance. 
Animal studies have shown a correlation between the NK cell 
activity of different strains of mice and the ability of the 
strain to reject NK sensitive lymphoma cells (Kiessling, et al.
1975).
Clinical Observations.
The immunological surveillance role of NK cells is further 
supported by various clinical observations. Patients with 
Ghediak-Higashi syndrome, which is characterised by impaired NK
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cell function, have an increased incidence of lymphoid malignancy 
(Roder, et al. 198O: Dent, et al. I966).
Role in tumour surveillance.
Following a renal transplant the recipient receives 
immunesuppresive therapy to prevent graft rejection,this results 
in a depression of NK cell function and an increased risk of 
developing both reticuloendothelial tumours and carcinomas 
(Lipinski, et al. I98O: Penn, 1977)* These results are
suggestive that NK cells form at least part of an inimune 
surveillance system. Other conflicting evidence does not support 
this view; i) the vast majority of carcinoma patients have normal 
levels of NK cell activity in the early stages of the disease 
\rross and Baines, 197c). ii) freshly isolated xumcurs arc 
relatively insensitive to NK mediated lysis (Vose and Moore,
198c), iii) lymphocytes isolated from tumour biopsies lack NK 
cell activity (Moore and Vose, I981) and iv) interferon is 
relatively ineffective at inducing NK cell activity against 
autologous biopsy derived target cells (Vansky, et al. I980).
However, established tumours that have evaded the surveillance 
^stem are likely to be resistant in vitro. They are therefore 
inappropriate models for the immunological processes involved 
in in vivo, prevention and surveillance. The case for an NK 
cell mediated surveillance system therefore remains unproven.
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Role in viral infections.
The observation that NK cells undergo activation during the 
early stages of viral infection has led to speculation that they 
may also play a role in the host's defences against viruses 
(Welsh and Zinkernagel, 1977)• NK cell activation during the 
early stages of a viral infection may be due to virally induced 
interferon production. However, inactivated virus may also 
cause an elevation of NK cell function in the absence of 
detectable interferon production (Kirchner, et al, I982).
Evidence supporting NK cell recognition of virus infected cells 
has come from studies in which it has been shown that virus- 
infected targets are more susceptible to lysis than their 
uninfected counterparts (Welsh and Hallenbeck, I980).
Susceptibility of a host to viral infection may be infDuanoed 
by the genetically—determined level of natural cytotoxicity, and 
depletion of NK cell function in vivo, should result in reduced 
host resistance. Ten out of eleven mouse strains showed a 
correlation between resistance to murine cytomegalovirus and 
the level of virus-induced NK cell activity (Bancroft, et al.
1981). ^eige mice, which are naturally NK deficient, showed an 
increased susceptibility to infection with the same virus (Shellam,
et al. 1981).
Role in haemopoiesis.
NK cells have also been shown to have a role in the survival
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of haemopoietic or lymphoid grafts. The success of human bone 
marrow grafts has also been shown to be related to the NK cell 
activity of the recipient (Dokhelar, et al. I981). Haemopoietic 
or lymphoid grafts fail to survive in lethally irradiated FI 
hybrids of certain murine strains (Cudkowicz and Bennett, 1971)« 
This phenomenon, known as hybrid resistance, was subsequently 
found to be effected by NK cells (Lotzova, et al. I983).
NK cells have the ability to destroy bone marrow cells 
in vitro. (Hansson, et al. I98I). This observation together 
with their role in hybrid resistance has raised the possibility 
of a primary physiological role for NK cells in the regulation of 
the differentiation of normal haemopoietic tissue. If true, the 
cinxi-'tumour rui'-i an»i-vlral activily tiiey also possess may be a 
fortuitous by-product of their capacity to interact with membrane 
determinants and to lyse those cells carrying inappropriate 
markers.
Supporting evidence has come from studies which demonstrated 
that NK cells can inhibit granulocyte macrophage colony forming 
cells (Hansson, et al. I982) and that NK like cells may regulate 
haemopoiesis in aplastic anaemia (Bacigalupo, et al. I980).
An NK lymphocytosis associated with a neutropenia has also been 
described (Pross et al. 1981).
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NK cells may also have a regulatory influence on B-cells.
It has been observed that they can suppress the response of B-cells to 
pokevreed mitogen (Aral, et al. 1983,). Cells expressing the HNK-1 
(Leu-7) marker have been observed in the follicular areas of human 
lymphoid tissues (Ritchie et al. 1983)» where, it has been suggested, 
they may play a role in B-cell differentiation*
In addition to cytolysis NK cells may also be able to perform 
an immunoregulatory role through the production and release of 
soluble factors. Studies have revealed that lectin stimulation of 
highly purified populations4LGL results in the production of a number 
of lymphokines! eg. IL-2, interferon and colony stimulating factor 
(Kasahara, et al. 1983), It would not be unreasonable therefore to 
suggest that under appropriate conditions NK cells may, through the 
action of lymphokines, be able to influence the immunological 
microenvironment *
NK cells are therefore not the laboratory artifacts they were 
first thought to be, they are in fact a subpouulation of mononuclear cells 
with the characteristics of LGL and the ability to lyse , spontaneously, 
a variety of target cells, and are able to produce various lymphs 
It has been suggested that they may be involved in immunosurveillance, 
patients with Ghediak-Higashi have an increased incidence of lymphoid 
malignancy (Bent et al. 19^6), haemopoiesis, NK cells have been shown 
to be able to destroy bone marrow cells in vitro (Hanson et al. 1981), 
and possibly regulation of antibody production, NK cells can suppress 
the B-cell response to pokeweed mitogen and have been found in the 
follicular areas of lymphoid tissues (Aral, et al. 1983; Ritchie, et al.
1983). As yet there have been no reports of any correlation between low
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M  cell function and susceptibility to disease, although it has 
been shown that virus infected cells are more susceptible to lîK lysis 
than their uninfected counterparts (Eelsh and Hallenbeck* I980) and that 
the ability of mice to resist viral infection correlates well with 
NK cell activity (Bancroft, et al. I98I).
Quite how NK cells recognise their targets is, as yet, unknown.
It has been suggested that effector cell recognition of target borne 
transferrin receptors may be the mechanism as a direct correlation 
has been found between transferrin receptor expression and susceptibility 
to NK cell lysis, however it was not possible to inhibit lysis with 
either excess iron, saturated transferrin receptors or affinity 
purified transferrin receptors (Borysiewicz, et al. I986). Recent 
reports have suggested that the T-cell receptor for antigen is involved, 
however. Young and his coworkers (1986) have shown that a functional 
T-cell receptor p chain is absent in fresh LGL making it extremely 
unlikely that the T-cell receptor is envolved in target cell recognition.
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Atonic Dermatitis.
One Buch disease which may allow insights into the mode of 
action of NK cells is atopic dermatitis (AN). Patients with AD 
are recognised as having an increased incidence of certain 
cutaneous viral infections such as warts and molluscum 
contagiosum (Currie, et al. 1971: Soloman and 'iTâlner, I966).
They also handle certain other viral infections abnormally. 
Vaccinia virus is now almost of historical importance but both 
this and the much more con .mon herpes simplex type I can result 
in Kaposi's varicelliform eruption, a serious and potentially 
fatal condition in a patient with AD (Baer, 1959: Pajka, 1975)*
As NK cells have the ability to lyse certain tumour and virally 
infected cells (Roder and Pross, I982) it was of interest to 
determine whetner NK cell function was altered in patients with 
AD and if possible to elucidate the nature of the defect.
Atopic dermatitis is a pruritio cutaneous condition with 
characteristic clinical features and a chronic relapsing course. 
Classically it is seen in patients who also have a personal or 
family history of "atopic disease" that is, asthma, allergic 
rhinitis and urticaria. AD usually presents at a very early age 
one study (lîajka, 1975) has shown that 6(Jj. of patients had onset 
of AD in the first year of life and that 85^ of patients with AD 
were under five years old. Some patients become free of AD 
during childhood and studies of patients from 15 to 20 years old
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have shown that about 40^ show a clearing of the disease (Musgrove 
and Morgan, 1976). Adult onset of AD does occur, but it is unusual.
Immunological features of Atopic Dermatitis.
Humoral.
Serum IgE levels are elevated in 80% of patients with AD 
(Juhlin, et al. 1969). The evidence for the existence of an 
antigen—IgE-mast cell mechanism as the primary cause of AD is 
at best tenuous for several reasons. Firstly, raised IgE levels 
are seen in patients whose conditions have no historical or 
clinical evidence for AD or allergic respiratory disease, eg. 
patients with parasitic infections. Secondly, serum IgE levels 
remain high during remissions although, during prolonged disease 
free periods, levels gradually falj oowards normal (Johansson 
and Tuhlin, 1970). Thirdly, AD occurs in patients with low or 
undetectable levels of serum IgE, including those with 
agammaglobulinaemia (Peterson, et al. I962), It would therefore, 
appear that the raised serum IgE levels seen in AD may be due to 
a fault in the control mechanism of IgE production rather than 
the cause of the disorder.
Cell mediated.
Cell mediated immunity in patients with atopic dermatitis 
may also be abnormal. As early as l895 patients with AD were 
observed to be unusually susceptible to severe cutaneous
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infections with herpes simplex and vaccina (Kaposi, 1895)»
These patients also have an increased incidence of warts and 
Molluscum contagiosum (Currie, et al. 1971: Solomon and Telner.
1966), Increased incidence of delayed type hypersensitivity 
(DTH) reactions in patients with AD was thought to be a result 
of the atopic idisorder (Epstein and Mohigern, I964), however, in 
retrospect these findings are now thought to represent the high 
frequency of exposure to sensitising agents, ie. topical 
medications such as neomycin, among patients with AD. In fact, 
it is now thought that there is a decrease in DTH in patients 
with AD, this was suggested as long ago as 1937 when it was 
observed that there was a low incidence of contact sensitivity 
in patients with AD (Rostenberg, 1937). Since then it has also 
been shown uhac xiiere is ct low incidence of seusiiisation to 
poison oak and dinitrochlorobenzene in AD (Jones, et al. 1973: 
Palacios, et al. I966). Depressed DTH responses to tuberculin, 
streptokinase-straptodornase (SKSD) and Candida have also been 
noted, however, the ability of lymphocytes from patients with 
AD to transform in vitro in response to these allergens has been 
shown to be relatively normal, despite cutaneous anergy (Elliott 
and Hanifan, 1979 a).
Depressed in vitro cellular immune responses have been 
reported. Tv-jo patients with severe AD both showed total cutaneous 
anergy and their lymphocytes failed to respond when cultured
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with the mitogen phytohaemagglutinin (PHA) during periods of 
disease activity. However, during remission ■ the lymphocyte 
transformation improved (Lobitz, et al, 1972). Elliott and 
Hanifan (l979 b) found that the abnormal responses to PHA were 
reversible in vitro if the cells were kept in culture for 
two to four days. One explanation to have been put forward for 
these results suggests that there are immature circulating 
lymphocytes that are deficient in mitogen responsiveness,
(Elliott and Hanifan, 1979 a).
It has been observed that the chemotactic response of 
neutrophils and monocytes from patients with severe AD is 
depressed and that this depression of chemotaxis is reversible 
with clinical improvement (Kogge and Hanifan, 1976;. Eviaenoe 
has been put forward suggesting that a serum derived inhibitory 
factor is responsible for the depression of chemotaxis in these 
patients (Snyderman, et al, 197/)•
A more recent in vitro observation has been the report of 
reduced levels of suppressor T—cells or suppressor T—cell 
activity in patients with AD (Canonica, et al. 1979: Eaure,
et al. 1982: Rola~Fleszcynski and Blanchard, I981), This area 
of investigation is confused by poor definition of the patients 
studied with few details of presence or absence of respiratory 
and cutaneous symptoms and the severity of the atopic dermatitis,
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The methods used to investigate the T-cell subsets have also 
varied in these studies, with some groups using the T/t and Ty 
method of quantitation. (Cooper, et al. I983) and others using 
monoclonal antibodies (Leung, et al. I98I). The T_^  , Ty method 
of quantitation relies on the observation that T cells that carry 
receptors for IgM function as helper cells while T cells that 
carry receptors for IgG function as suppressor cells. This 
method however is not as accurate as that using monoclonal 
antibodies. It has been suggested that the low numbers of, and/or 
defective suppressor T-cells may be responsible for the high serum 
IgE levels in patients with AD. However, as the maturation of 
suppressor/cytotoxic T- cells is dependent on the helper/inducer 
subset as well there may also be a defect in the helper/inducer 
population. A defect in this population would explain the 
observations of decreased antigen and mitogen responsiveness of 
peripheral blood lymphocytes (PBL) from patients with AD. (Elliott 
and Hanifan, 1979&: Elliott and Hanifan, 1979b).
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Scope of present thesis.
Natural killer cell activity in atopic dermatitis.
Studies of PBL NK cell activity in patients with AD have given 
conflicting results. Some groups report that NK cell activity against 
a tumour cell line target is reduced (Kusiami and Trentin, I982). Others 
have found normal or raised levels of NK cell activity against tumour 
cell line targets (viander, et al. 1982: Strannegard and Strannegard,
1980). While others have reported that against autologous and allogenic 
skin fibroblasts it is raised (Leung, et al, 1982),
In summary, individuals with AD are recognised as having abnormal
humoral immunity and altered cellular reactivity, as well as a 
susceptibilty to viral infection. Defective NK cell activity may explain
the link between susceptibility to viral infections and AD as it is well
known that NK cells will lyse virally infected cells (Welsh and Hallenbeck^ 
1980). The possibilty exists that defective NK cell activity is an 
integral part of the disease or it may be an epiphenomenon related to 
AD, therefore to try and resolve this question this thesis examines
1) NK cell activity in AD in comparision with age and sex matched 
controls using the assay described below,
2) The methodology of the cytotoxic assay to determine whether 
variations in the method (eg. incubation length, removal of 
phagocytic/adherent cells or the use of target cells other than 
K962) caused the variations reported in NK cell activity in AD,
3 ) Sequential NK cell activity in a group of patients
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with AD to establish if a correlation exists between 
clinical activity and M  cell activity.
4) Effector cell numbers in AD patients and normal
controls using the monoclonal antibodies HNK—1 
(Leu-7) and Leu—11b.
5 ) The possible presence of serum inhibitors specific 
for NK cells,
6) The effect of topically applied steroids (the mainstay 
of treatment of AD) on the NK cell activity of normal 
volunteers.
7 ) The effect of betamethasone in vitro, and because
of the recognised effect of stress in causing the
disorder to flare and the role histamine has in 
allergic disorders, the effect of adrenaline, nor­
adrenaline and histamine were also studied in-vitro.
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Materials and Methods.
Resume of methods available for the study of NK cells. 
Introduction.
There are several methods available for the estimation of 
natural killer cells both function and numbers. These are;-
1. Cytolysis.
2, Cherailuminescence.
3. Target cell/effector cell conjugates.
4, Monoclonal antibody techniques.
5# Histological stains.
1. Cytolysis.
Cytolysis estimates the natural killer cell's ability to 
lyse certain target cells, usually a tumour cell line, such as 
K562, There are a large number of cell lines available for use 
in cytolytic assays, ranging from naturally occuring tumours to 
virally transformed cell lines including T- and D-cells, and 
some non-T non-B lines such as the myeloid cell line K562.
The most common cytolytic assay is one based on isotope 
release. Tumour cells are labelled with a radioactive isotope, 
usually chromium 51 in the form of chromate (^^Cr04~^),
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Chromium binds to large molecular weight intracellular proteins 
and is released when the plasma membrane is damaged. Chromium 
released from damaged cells is not reutilised, therefore the 
amount of chromium released is nearly proportional to the number 
of cells- damaged.
Parameters affecting the outcome of cytolytic assays.
There are a number of methodological factors which can affect 
the outcome of the chromium release assay:-
a) The size and geometry of the wells in the microtitre plate.
Three types of microtitre plate are available, flat, round 
and V bottomed. As cytolysis depends upon effector: target cell 
contact, the geometry of the well will therefore influence the 
outcome of a cytotoxicity assay a W contact is facilitated in 
plates with round or V bottoms they will have a greater influence 
on the result of an assay.
The size of well may also be an important consideration.
In a smaller vessel the chance of effector cell/target cell 
contact is increased. However, it has been shown (Miller and 
Dunkley 1974) that in plates with cou'caye. bottoms volume does not 
matter as the cells tend to pellet during the assay. It has also 
been shown, however, that if the culture is kept in suspension 
the amount of chromium released is inversely dependent on the 
volume.
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b) Presence of macrophages,
NK cell activity can be suppressed in vitro, by the presence 
of macrophages or monocytes in the effector cell population 
(Jondal et al. I982). Conversely removal of macrophages or 
monocytes by either (a) incubation with carbonyl iron followed 
by passage over a strong magnet or (b) incubation on glass or 
plastic for one hour at 37°G results in an increase in natural 
killer cell activity.
The mechanism by which macrophages suppress natural killer 
cell activity is uncertain. There are three possibilities.
(1 ) Macrophages may bind target cells thereby masking them from 
the effector cells. (2 ) Macrophages and monocytes may produce 
prostaglandins which inhibit NK cell notivity (Droller et al. 
1978). Or (3), it may be a combination of both these factors.
o) Choice of target cell.
While natural killer cells show a specific ability to lyse 
tumour and virus infected cells, their ability to kill is not 
uniform, i.e. effector cells from the same source will lyse 
different target cells to varying degrees (Allavena and Ortaldo 
(1984). Certain target cells are also more resistant to lysis by 
NK cells than others (Jondal et al. 1978).
d) Incubation length.
There are two controls included in the cytolytic assay. The
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first, spontaneous release (SR), measures the amount of isotope 
that leaches out of the target cells during the course of the 
assay. The second, total activity (TA), measures the amount of 
isotope that would be released if all the target cells were lysed. 
Incubation length is important from the point of the level of 
spontaneous release; the longer the incubation the more likely 
it is that isotope will leach out of the target cells and give 
rise to a high spontaneous release. Also NK cells are well 
documented as being multi-hit, therefore, the longer the incubation 
period, the higher the percentage isotope release (Ullberg and 
Jondal 1981). It is possible therefore, that during longer 
incubations, differences in NK cell activity could be masked 
because of this. Four hour incubations are therefore, more prefer» 
able than eighteen hours fcr these reasons,
e) Use of "filler cells".
The two controls for cytolytic assays, SR and TA, are both
important as they are the standards against which the activity
of the effector cells is measured. Spontaneous release of 
chromium, if too high may mask effector cell activity. The
choice of target cell and the length of assay are, therefore,
important. Spontaneous release however, can be reduced by the 
addition of what are termed "filler cells" (Dunkley et al. 1974). 
"Filler cells" may be fixed white blood cells or populations of 
cells with no active NK cell function such as mouse thymocytes.
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2 , Chemiluminescence.
Chemiluminescence has been recently suggested as an alter­
native method of measuring NIC cell activity. Following phago­
cytosis of bacteria by polymorphonuclear leukocytes there is a 
burst of superoxide production which is involved in the killing 
of the ingested bacteria. NK cells have also been shown to 
generate superoxide when mixed with target cells (ïïelfand et. 
al. 1982). It is unknown whether or not this is involved in 
the killing step. This burst of superoxide generation can be 
measured using a chemiluminometer.
The disadvantage of this method is that it is indirect, ie. 
it does not show if any actual killing takes place. Patients 
with Chodiak-I'IjLgashi syndrome have defective NT.' cell activity 
as measured by chromium release (Poder et al. I980), although 
using chemiluminescence it has been shown that superoxide 
generation does occur (Roder et al. I9 83). Recent evidence 
suggests that the cytolytic mechanism is not oxygen dependent. 
Patients with chronic granulomatous disease, a disorder where 
phagocytic cells fail to produce toxic oxygen derivatives, have 
normal natural killer cell function (El-hag and Clark. I984). 
It has also been shown that the addition of catalase or super­
oxide dismutase to NK cell assays -has no effect on natural 
killer cell-mediated cytotoxicity (Abrams and Brahmi 1984).
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3. Target oell/effector cell conjugates.
Conjugation assays examine events at the single cell level.
They are dependent on the fact that NK cells bind to their 
targets prior to lysis. Equal numbers of effector cells and 
target cells are incubated together for thirty minutes at 37^ 0.
The resulting cell mixture is examined microscopically under 
phase contrast and the percentage of lymphocytes that have formed 
conjugates with the much larger tumour cells can be estimated 
(Grimm and Bonavida 1977). See plate two.
This assay provides a useful estimation of the number of 
cells capable of binding to the target cells. It gives, however, 
no measure of their ability to kill the target cells. Lymphocytes 
from pac.-.aucs with Ghediak-Ligashi syndrome bind to the taiget 
cells normally but cannot then lyse the target (Roder et al. I983).
A modified version of this assay overcomes this disadvantage 
and allows the visualisation of cytolysis (Grimm and Bonavida 1979). 
Target cells and effector cells are allowed to interact together 
in agarose rather than medium. The agarose with the effector cell/ 
target cell conjugates is then plated out and incubated for
various times at 37°G. The plates are then stained with trypan 
blue and fixed with formaldehyde. Only the killed target cells 
are stained with the trypan blue, and as the agarose prevents 
the effector cell from moving away from its target both the number 
of effector cells and active effector cells may be counted.
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Plate two.
o
Effector cell/target cell conjugate, photographed using 
Nomarski differential interference contrast optics. 
Magnification xl.OOO, bar represents 20pm.
T= target cell 
E= effector cell
3 La
4. Monoclonal antibody technicrues.
There are now several monoclonal antibodies available that 
are specific for cell surface markers on natural killer cells, 
eg. HNK“1, Leu-1la and Leu-1lb (Abo and Balch I98I,, Lanier et 
at. 1983). These can be used in fluorescent or peroxidase 
techniques to measure the percentage of positive cells within 
a population. See plate three.
An advantage of the fluorescent antibody method is that 
after labelling with the fluorescent conjugate, the cells can be 
separated into two populations on a fluorescent activated cell 
sorter (PAGS): NK marker positive and NK marker negative.
Functional studies can then be carried out on the enriched and 
depicled populeh ion^ of cells (Loken and Herzenberg 19 .'5**
Ortaldo et al. I981).
5. Histological stains.
Finally natural killer cells can be studied stained with 
histological stains, such as giemsa. Human NK cells have been 
shown to have the unique morphology of large granular lymphocytes 
(LGL) (Timonen et al. 1979). See plate one. In practice 
this stain may be used on cytocentrifuge preparations although 
it is a purely quantitative method and gives no estimation of the 
functional ability of the counted cells. However, as only about 
5^ of peripheral blood lymphocytes (PBL) have the morphology of 
LGL and as activated cytotoxic T-cells also have this morphology 
it is difficult to gain a true insight as to the actual numbers 
present in the circulation.
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Plate three.
Fluorescent micrograph of PBMC stained with Leu-lib and 
FITC conjugated goat anti-mouse IgM. Magnification x^OO, 
bar represents 20pm.
Micrograph shows both Leu-lib positive cells, with associated 
fluorescence and red counter stain, and negative cells red counter 
stain only.
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Materials and Methods used in this study.
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Cell culture medium.
The medium used throughout was R.P.M.I, I64O (CIBCO, Paisley 
Scotland) obtained as a times ten concentrate and made up to the 
working dilution as follows:—
Twenty ml. of the concentrate was added to I80 ml. of a 
solution made up of 2.65 g/l» Hepes (Flow laboratories) and
0 .8 5 g/l. of sodium hydrogen carbonate (BDH Chemicals, Poole, 
England). The pH of the medium was then adjusted to 7 ,5 by 
the addition of 5M sodium hydroxide.
Separating mixture for isolation of mononuclear cells from venous 
blood.
The separating mixture used for the isolation of peripheral 
blood mononuclear cells was fTcoll/isopaque.  ^This was made up 
of a 9^ solution of ficoll (Pharmacia Fine Chemicals, Milton 
Keynes) and a xy solution of i’sopaque (Nyegaard & Co. AS. Oslo) 
which was made up by adding 48 ml. of distilled water to 4(D ml. of 
isopaque 440.
83 ml. of isopaque were added to 2!oo0 ml. of 9% ficoll to 
give 283- ' ml. of&mixture with specific gravity between I.O76 
and 1.078. This was then sterilised by filtration and stored in 
the dark at 4^ 0.
White cell counting fluid.
White cell counting fluid was made up of 1% solution of
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acetic acid in distilled water plus two or three drops of a 2% 
trypan blue solution.
Preparation of effector cells.
Venous blood was taken from both patients and, where possible, 
age and sex matched controls, and added to sterile bottles 
containing preservative free heparin (Evans, Speke, Liverpool).
The mononuclear cell layer was isolated by layering two volumes 
of whole blood over three volumes of Picoll/lsopaque and 
centrifuging at 200g for 30 minutes in an MSE multex centrifuge.
The mononuclear cell layer was removed and the cells washed 
twice in RPMI containing 100 units of preservative free heparin/ 
ml. (Weddel Pharmaceuticals Ltd., London) to prevent aggregation 
of colls. The cells were then given a final wash in RPMI 
containing 5/“ heat inactivated foetal calf serum (OIBCO)
L-glutamine 2mmol/ml, (GIBCO) and 2 • of penicillin/
steptomycin (GIECO). For overnight incubations Bql of gentamicin 
was also added (Nicholas Laboratories).
Purity was assessed visually using white cell counting fluid 
and was never less than 95% mononuclear cells. Viability was 
assessed using trypan blue exclusion and was also never less than 
95%' The final concentration of cells was adjusted to 2xlO^/ml. 
two dilutions of this suspension were made to achieve concentrations 
of 1x10^ and ^xlO^ cells/ml.
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Removal of phagocytic and adherent cells.
Two methods were employed for the removal of phagocytic and 
adherent cells*
1 ) Carbonyl iron ingestion.
Isolated mononuclear cells were incubated with 5 mg/lO cells 
carbonyl iron (GAP Manchester) for 20 minutes at 37^C. followed by 
passage over a strong magnet which removed the phagocytic cells*
2) Adherence to glass or plastic*
Adherent cells were removed by incubating the isolated 
mononuclear cells in glass or plastic universale for one hour at 
37*^ 0. In each case the recovered cells were washed twice in medium 
containing supplements before being resuspended and counted.
Target cells.
K ^ 6 2  were used as the target cells in all the standard 
cytotoxicity assays. Other cell lines used in this study were BJAJB, 
CCRP-CEM, MOLT-U and Namalva. See table one for characteristics of 
each cell type* All cell lines were maintained in continuous culture 
in RPMI 16L0 medium containing 10^ heat inactivated foetal calf serum 
200 units of penicillin/streptomycin and 2 mmol/ml. of L-glutamine. 
The cells were kept at a temperature of 37°C. in an atmosphere of 
9% COg 95% air, and were subbed routinely every two days or 2L hours 
before being used in an assay.
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Table 1.
Target cell line characteristics.
Immunoglobulin
Cell Line Type EBG H L SIG SEC
BJAB^ BLCL - M K + +
CCRP-CEM^ TLCL - - — - —
K562^'4 CML - - - — -
MOLT-4^ T-AL - - - — —
Namalva^ BL + M L + +
Key*. BLCL
TLCL
C'Mli
T-AL
BL
EBG
SIG
SEC
B-Lymphoblastoid cell line 
T"Lymphoblastoid cell line 
Chi'onic myeloicL leukaemia 
T-acute Lymphatic Leukaemia 
Burkitt's Lymphoma 
Epstein Barr Genome 
Surface Immunoglobulin 
Secreted Immunoglobulin
1. Menezes et al. (l973)
2. Foley et al. (1965)
3. Lozzio and Lozzio (1975)
4 . Andersson at al. (l979)
5. Minowada et al. (l972)
6. Nyormoi et al. (1973)
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Labelling of target cells.
An aliquot of the cell culture medium containing 3x10^ cells 
was incubated with 0.2 ml.of Or. (NagCrO^, radiochemical Centra, 
Araersham) containing 20 megabequerals per ml. at 37°^. for one hour. 
The cells were then washed six times with RPMI plus supplements. 
After the final wash the cells were resuspended in 10ml. of 
medium and counted. The final concentration was adjusted to 
2x10^/ral.
Standard cytotoxic assay.
The cytotoxic assay was carried out in V bottomed microtiter 
plates (Plow). 0.1' ml. of effector cells at the various dilutions, 
2x10^/ml,, 1x10^/ml. and 9x10^/ml. , were incubated with 0.1 ml. of 
labelled target cells, at 2x10^/ml. for L hours at 37°G. in an 
atmosphere of 00^ 95% air. This achieved effector to target 
cell ratios of 100:1, ^0:1 and 2$;1. Two controls were included, 
the first estimated the degree of spontaneous release (SR) of 
radioisotope from the target cells which were incubated with 0.1 ml. 
of RPMI alone. The second estimated the total activity (TA) by 
completely lysing the target cells with the addition of NaOH to 
wells containing 0.1 ml. of target cells at a concentration of 
2x10^/ml. 100% release of bound isotope was regularly achieved.
All tests and controls were carried out in quadruplicate.
Following incubation 0.1 ml. of cell free supernatant was 
removed from each well and counted for three minutes in a 
gaimnaoounter (LKB 1282 compugamma) to assess the radioisotope 
release.
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Modification of cytotoxic assay: to test In Vitro, effects of
various pharmacological agents.
The microtiter plates were set up as stated for the standard
cytotoxicity assay with the following modifications:
0,09 ml. of effector cells at the various concentrations were
aliquoted along with 0,01 ml. of the following four pharmacological
agents. I) adrenaline, original concentration of 1 mg./ml.
(Antigen Ltd., Roscrea, Ireland). II) Noradrenaline in the
form of noradrenaline acid tartrate, original concentration
of 1 mg./ml. (Winthrop Laboratories, Surbiton-upon-Thames, Surrey).
Ill) Histamine, in the form of histamine acid phosphate, original
concentration 1 mg./ml. (BDH Chemicals, Poole, England). This was
made up in phosphate buffered saline pH 7-4 and filter sterilised
before use, auC IV) b^tsaasol, in 'the form of betamethasone sodium
phosphate, original concentration of 4 mg/ml. (Glaxo Laboratories
Ltd., Greenford, England). The pharmacological agents were added
to each well so as to effect final concentrations of 10 10
-4 “510 and 10 of the o-riginalv' The plates were then incubated at 
37°C for one hour before the addition of O.O9 ml, of labelled 
target cells and 0.01 ml. of medium to each well.
The control wells, to estimate the degree of SR and TA, each 
received 0.02 ml. of medium. Also included in the controls for 
this experiment were wells containing O.O9 ml. of effector cells 
at the various concentrations plus 0,09 ml. of target cells plus
0.02 ml. of medium, to act as a control for the wells with the
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various pharmacological agonis added to them. The four 
pharmacological agents themselves had no effect on SR or on 
effector cell viability.
Further variations of this assay were:-
1) microtitre plates were set up as outlined above, with the
following modifications, 0.02ml. of the various pharmacological
agents used were uadded at the same time as the 0,09 ml. of
target cells, and only one concentration of each agent was used 
—2
namely 10 final concentration of the original.
2) the effector cells were incubated for four hours with the
_2
various drugs at a final concentration of 10 of the original 
at Followed by thr&& in RPMÎ supplements
before being counted and plated out in a standard cytotoxicity 
assay.
Modification of cytotoxicity assay to test effects of incubation 
Of effector cells in medium supplemented with lOfo homologous 
autologous or foetal calf serum.
In the standard assay the medium is supplemented with 5^
FCS, in the following protocol the medium was modified and 
supplemented with either (a) IC^ o patient's serum, (b) 10^ control 
serum or (c) IC^ o PCS. The standard cytotoxicity assay was then 
carried out with patients effector cells in medium containing 
either patient's serum, control serum or PCS and control effector 
cells in medium containing patient's serum, oontrol serum or PCS.
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Two further modifications of this assay were used.
1) Plates were set up as outlined above and incubated with p.1 ml. 
labelled target cells overnight at 37°C* "Filler cells" were used in 
the spontaneous release wells of overnight assays to reduce the level
of spontaneous release. The "filler cells" used were mouse thymocytes
isolated on the day of the assay and added to the SR wells at a ratio
of 100 thymocytes to 1 target cell.
2) Effector cells were incubated overnight in the various 
supplemented media at 37^0. The labelled target cells were added the 
following day and a standard cytotoxicity assay carried out.
Regime for the testing of the effect of topically applied steroids 
on the} KK cell activity of normal subjects.
Ten normal healthy volunteers with no past history, personal or 
family, of atopic disease were asked to apply grams of betamethasone 
valerate (Glaxo laboratories) to their trunk immediately following 
a hot bath for seven nights. ( The full details of the study group 
are given in table 1^). Venous blood samples for the estimation of 
NK cell activity were taken at regular intervals, days 0, 3, 7, 11,
18 and 22. Blood samples were always taken between 9.00 and 10,00
am.
The above protocol was repeated with a further four volunteers 
using the base of the ointment (i.e. containing no active steroid). 
Regular blood samples were again taken on days 0, 3* 8, 1^, 18, and 
22 for the measurement of RK cell activity. Again the samples were 
taken between 9*00 and 10.00 am.
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Calculation of results.
Results were expressed as percentage lysis according to the 
following formula where CPM is counts per minute, SR is spontaneous 
release and TA total activity.
9^1ysis = 0PM of sample - Mean CPM of SR ^
Mean CPM of TA - Mean CPM of SR
IgE methodology.
The total serum IgE level was measured hy the paper radio­
immunosorbent test (p r i s t) technique using commercially avaible kits 
(Pharmacia diagnostics AB, Uppsala, Sweden).
Briefly, SO ul of patient's serum which had been diluted 1:10 
with an IgE free diluent (horse serum) was layered onto a paper disk 
coated with anti-human IgE antibody. The disk and the patient's serum 
were then incubated together for three hours at room temperature.
Following incubation the disk was then washed three times prior to 
12^So jil of ^I-labelled anti-human IgE being layered onto the disk, 
which was then incubated overnight at room temperature. The following 
day the disk was again washed three times in PBS prior to being 
counted in an LKB minigamma gamma counter,
A standard curve was set up at the same time using samples with 
a known amount of IgE and the level of IgE in the patient's sample 
was then estimated from this standard cruve. In the event of the level 
of the patient's IgE being higher than the top standard further 
dilutions of the serum were made and the assay repeated.
The normal range for IgE in serum using the Pharmacia PRIST 
method is O ' 110 lU/ral,
Fluorescent antibody technique.
The indirect method of staining cells was used. Briefly, 
i+x10^  cells were incubated with either S  of HNK-1 ( a gift 
from Dr. J.C. Roder.) or $  pi of Leu-11b (Beckton/Dickdnson) 
for U S  minutes at room temperature, both monoclonal antibodies 
had 200 ug of protein per ml. Following incubation the cells 
were washed twice in cold PBS before being incubated with ^0 pi 
of a 1:S0 dilution of an FITC conjugated goat anti-mouse IgM 
antibody '( Melloy Labs diagnostic division, Springfield, 
Virginia, USA.) for one hour at The conjugate contained
> 0.14 mg of specific antibody per ml. Following the second 
incubation the cells were washed a further two times in cold 
PBS prior to cytocentrifuge preparations being made. These 
preparations were then fixed in methanol for five minutes and 
then counterstained with a 0.b0T% solution of thyazine red 
(Raymond A. Lamb, London.) for one hour at i|^ C. The preparations
were then examined under ÜV light using a Leitz ortholux
0
fluorescent microscope, 200 cells were counted and the number 
giving positive staining was expressed as a percentage of the 
total.
Clinical details of patients.
All patients had long standing atopic dermatitis, diagnosed 
on the basis of the following criteria':.—
Age of onset in early childhood, previous or current flexural 
involvement, previous or current lichénification, a positive 
past and/or family history of other atopic diseases and a raised 
serum IgE level, 200 I.U./l.
Clinical scoring of patients.
Sixteen bcjy sites were exarlined on each vis'.t to the clinic 
and scored for the following features: extent of involvement,
erythema, pustulation, excoriations, dryness and cracking on a 
0 to 3 scale. See figure one. The values are then added and the 
total is the patientb clinical score. The higher the total 
therefore, the worse clinically the patient.
As this method of scoring patients is subjective, patients 
were therefore assessed by the same clinician on each occasion 
they visited the out-patients department of the hospital.
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Figure 1.
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Assessment form showing the body sites and the symptoms used 
to establish the clinical condition of patients with AD.
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Statistical analysis of results.
The statistical significance of the results obtained in this 
study were determined by either the paired or unpaired Student's 
t-test, where the data was normally distributed, or by the 
Mann-Vhitney test when it was not.
Correlation coefficients were obtained using Pearson's 
product moment correlation test.
All statistical analysis was carried out on a North Star 
advantage microcomputer.
hS
CHAPTER THREE
NATURAL KILLER CELL ACTIVITY OP PERIPHERAL 
BLOOD MONONTtgleAR CELLS PRO^ -' PATIENTS WITH 
ATOPIC dermatitis.
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The aim of this experiment was to ascertain whether or not 
NK cell activity was reduced in patients with atopic dermatitis.
Clinical Details of Patients.
Twenty patients with atopic dermatitis were studied, I4 
female, 6 male, with an age range of 14 to 54 years (mean age 
26 yrs). All of the patients had long standing atopic dermatitis,
i.e. a chronic relapsing pruritic skin condition with the typical 
features of AD, Additional diagnostic criteria included age of 
onset in early childhood, previous or current lichénification, a 
positive past personal and/or family history of other atopic 
diseases, a raised serum IgE level >"200 lu/ml. All six criteria 
were present in eleven of the patients, five were positive in 
another five patients, of the remaining four patients, two were 
positive for four features and two for three. Seventeen patients 
had a past history of other atopic disease and seventeen had a 
positive family history of atopy. No patient was on systemic 
corticosteroid therapy at the time of the study, though one 
patient had received intermittent short courses of prednisolone 
for asthma. These details are summarised in table two.
Control Subjects.
Nine non-atopic controls were used on thirteen occasions, 
all controls were age matched within ten years of the patients’ 
age, the controls were also sex matched in six out of nine 
occasions.
TABLE 2
Number of patients 
Female:Male 
Flexural involvement 
Liohenification 
Age of onset (years)
< 2 
2 -  5 
> 15
Past history
Other atopic disease 
Family history
Other atopic disease 
Raised IgE
T>200 lU/ml
20
14:6
19 (95 /0) fill bu-t bio.
19 (9 5 ^ )  No
14
3
■ 1
All lo u t Nos*. IT , /7 jg./9,
No\. sr^ 6 ^ & I?
Nos.
17 ^857N a// loctb No>. 1-3
19 (95/°) Nt. )?.
Clinical details of patients with atopic dermatitis.
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Results.
The results of this experiment showed that NK cell activity 
was very much reduced in patients with atopic dermatitis as
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measured by Cr. release cytotoxicity assay. Figure 2. At
each effector to target cell ratio the mean value for the
patient group was significantly lower than that of the corresponding 
control group. p<O.OO^ j,. by -test.
From the individual results, displayed in table 3, it can be
seen that the mean NK cell activity of the patients was 4-4*1% at
100:1, 45*4^ at 50 :1 and 44*6^ at 25 :1 of the control values.
Plotting the results individually, as in figure three, it may 
be observed that ihore is some overlap between patients and 
controls, although the level of NK cell activity for the majority 
of the patients lies below the mean value for the control group.
Serum IgE levels and NK cell activity in AD.
Serum IgE levels were also examined in this group of patients. 
It has been suggested that serum IgE may be connected with disease 
activity although this is unlikely. The contradiction to this 
theory being the 2Cf}c or so of patients with normal levels of 
serum IgE (Juhlin, et al. I969). It was, however, thought to 
be a worthwhile exercise to ascertain whether or not there was a 
correlation between NK cell activity and serum IgE levels.
FIGURE 3
% Cr Release
24
20- Patient N  -  Z o
18-
Control A/ “  ^
14-
12-
25:1
Effector; Target Cell Ratio
Mean and SE of chromium release following a four hour 
cytotoxicity assay for patients with AD and normal healthy 
age and sex matched controls.
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TABLE 3
Atopies Controls
Age
(yrs) Sex 100:1 50 :1 25:1
Age
(yrs) Sex 100:1 50 :1 25:1
\ 19 P 3.5 3.0 1.7 20 M 19.6 1 6 .4 8.7
1 22 P 10 8 .1 2 .1 M >1
I 30 P 2.3 2.3 0.7 n V >1 "
4 21 M 3.4 1 .6 1.5 31 " M ' n
S' 27 M 5.9 4.5 2 .0 >1 'i] >1 '
6 20 P /.3 4.5 2 .0 - P 20.1 1 7 .0 9 .6
? 16 P 5.3 3.9 3.0 )) A .
8 23 P 13.6 6.7 4.1 28 P 30.8 19.1 6 .3
9 21 P 6,6 2.9 3.1 27 P 15.6 12.6 7.1
10 /5 P 8,6 11.0 9.0 47 P 6.8 5 .9 7.5
1 25 M 9.2 7.5 5.5 30 M 5.6 4 .6 3.3
a 5/ M /.8 4.6 2.0 56 M 37.7 28.3 16.5
13 42 F 7.2 3.5 37 F 21 10.5" 8 .4
21 P 32.7 27.6 18.3 22 F 38.7 2 5 .4 19.6
IS 25 P 5.8 2.3 1.5 24 P 9.8 7 .0 3.5
23 P 5.4 3.6 1.5 28 P 43.3 27 .4 17.7
fV 30 P 21.1 9.9 3.5 24 P 19.0 9 .8 2.1
/8 22 P 12.6 3.0 1.4 » U "
21 M 22.7 21.8 11.9 20 M 33.5 31.7 23.6
1/ M 19.1 18.8 l/.O w " : “
Mean 10.2 7.5 4.6 23.1 16.5 10.3
SE 1.7 1.6 1.0 3 .4 2 .5 1.8
Results for atopic Vs, normals for NK cell activity
/ 9b
FIGURE 3
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Percentage chromium release for individual patients (t ) 
and controls (C) at the various E.T, ratios. Mean values for 
each group are indicated by the bars.
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Raised IgE levels were found in nineteen of the twenty
patients, only one was within the normal range, i.e. 50 lu/ml.
\
In fifteen of the twenty patients, the IgE level was significantly 
higher than normal, (table 4) with the range being from 1,013 to 
35,000 lU/ml. (mean 8,812 lU/ml). Regression analysis was carried
out on these figures. No correlation could be found between
51 51percentage Cr. release and IgE level or percentage Gr. release
and log IgE level. ^ o- UO lii/wL).
Conclusions.
Results reported from different groups have been at variance. 
Kusiami and Trentin, in 1982 reported that NK oell activity is 
reduced in these patients. Others have reported normal or 
raised levels oi activity (Viander, et al. 1982: Strannegez-d and 
Strannegard. I98O).
The results of the above experiment have shown that the NK 
cell activity of patients with atopic dermatitis is greatly 
reduced compared with that of normal controls, as measured by the 
method used in this laboratory. It would also appear that the 
level of serum IgE has no effect on the level of NK cell activity 
of PBMC from patients with atopic dermatitis.
It is possible that variations in assay methodology could 
explain the normal or raised levels of NK cell activity found in 
some laboratories. It was decided therefore, to investigate this 
possibility further.
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TABLE 4
A&e Sex Log IgE
19 P 3,975 3.599
22 P 1,013 3.005
30 P 3,508 3.545
21 M 35,000 4.544
27 M 773 2.888
20 P 15,125 4.179
16 P 8,375 3.922
23 P 2,400 3.380
21 P 7 ,250 3.860
45 P 1,230 3.089
25 M 13,625 4.134
54 M 8,000 3.903
42 P 375 2.574
21 P 6,650 3.822
25 P 208 2.318
23 F 5,431 3.734
30 P 50 1.698
22 P 255 2,406
21 M 2,100 3.322
14 M 18,500 4.267
Serum IgE and Log serum IgE levels for patients with vLD,
50a
c h a p t e r  p o u r
THE EFFECT CP VARIATIONS IN ASSAY METHODOLOGY
ON THE NTC CELL ACTIVITY OP PATIENTS WITH AD
AND NORMAL CONTROLS
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Introduction.
There are differences in assay methodology between the 
groups of workers that reported normal or raised levels of NK 
cell activity in patients with AD and the assay methodology 
used in this study. The aim of the following experiments was 
therefore to ascertain whether or not differences in assay tech­
nique could account for the differences in results between the 
different groups of workers.
The major differences in assay methodology between this 
study and those of Viander et. al. (1982) and Strannegard and 
Strannegard. (198O) were:
1. Length of time of incubation of effector 
cells with targets.
2. Removal of phagocytic/adherent cells.
3. Use of target cells other tha-n K562.
Each of these variables was checked in turn to assess what
difference, if any, they made tè the amount of NK cell activity 
of patients with AD and controls.
1, Effect of increasing the incubation time on the level of NK
cell activity of PBMC from patients with AD and normal controls.
The reduced levels of NK cell activity in AD seen following a 
four hour assay could be due to abnormal activation of effector
52
cells ie. NK cells from patients with AD may require longer to 
reach control levels of cytolytic activity after the addition 
of the target cells and given a longer incubation time it might 
be possible for effector cells from patients with AD to "catch 
up" with those from normal controls.
NK cell activity was studied in nine patients (5 female, 4 
male) with AD and nine age and sex matched healthy controls in a) 
a four hour assay and b) an 18 hour assay.
Results.
Following an 18 hour cytotoxicity assay the NK cell activity 
of PBMC from the AD patients increased significantly compared 
vi/ith that fouTid following a  ^hosr- cytotoxic aa^ay, 1^«4 4 1'9 -,
at an E:T ratio of 100:1, p< 0.0005 using test
(table 5 ). The NK cell activity of the control subjects 
had also increased with the longer assay time (33.3 vs 61.4) with 
the same significant degree of difference. However, the level of 
NK cell activity in the control group was still higher (61,4 vs 
4 1.9 ) than that of the patients. It can be seen that the difference 
between the two groups following an I8 hour incubation was not as 
great as after a 4 hour incubation and did not reach the same level 
of significance p<0,02 (lOO:l) following 18 hours vs p<0.OO4 
(lOO:l) following 4 hours. (Figure 4 ).
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Table 5.
io of ^^Cr. Release
Patient Control
!
E:T Ratio 100:1 50:1 25:1 100:1 50:1 25:1
4 hours 14.4 10.9 5.9 33.3 28,1 19.2
18 hours 41.9 37.8 29 61.4 55.5 44.6
51Mean Cr. release during a four hour and eighteen hour cyto­
toxicity assay for patients with AD and age and sex matched controls
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F i g u r e
;5'Cr. RELEASE
70- 18hr Cytotoxicity Assay1%1 Patient 
I I Control
50-
4hr Cytotoxicity Assay
30-
100:1 50:1 25:1 100:1 50:1 25:1
E:T RATiO E:T RATIO
Mean +SE of chromium release following either a standard four 
hour cytotoxicity assay or an l8 hour cytotoxicity assay for 
patients with AD and age and sex matched healthy controls.
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2. Removal of phagocytic and adherent cells.
The presence of macrophages or monocytes in the effector 
cell population during a cytotoxic assay is known to cause 
suppression of NK cell activity (Jondal, et al. 1982). It is 
possible that the suppression caused by the presence of 
phagocytic or adherent cells in the effector cell population is 
greater in patients with AD than in normal healthy controls.
The phagocytic/adherent cells were, therefore, removed from the 
effector population prior to the cytotoxic assay, by
1. Carbonyl iron ingestion followed by passage 
over a strong magnet.
or
2. Adherence to glass, or plastic.
Carbonyl iron ingestion.
PBMC from eight patients with AD (5 female, 3 male) and five 
age and sex matched healthy controls (3 female, 2 male) were
51
treated as described above prior to the standard four hour Cr. 
release assay. The levels of NK cell activity found after removal 
of carbonyl iron reactive cells were compared to those found in 
untreated intact PBMC populations from the same patients and 
controls.
Results,
From figure $, it can be seen that carbonyl iron treatment
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Figure 5.
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Mean +SE of chromium release before and after the removal of 
phagocytic cells by carbonyl iron ingestion for patients with 
AD and age and sex matched healthy controls.
54a
of the effector cell population resulted in an increase in NK 
cell activity of PBMC from both the patients with AD and the 
control subjects. The difference between the patients and 
controls following carbonyl iron treatment had the same degree of j. 
significance as that found before treatment. P<r 0,005. These 
results are summarised in table 6.
Glass adherence.
PBMC from 9 patients with AD (5 females, 4 males) and 4 age 
and sex matched controls (2 females, 2 males) were treated as
51described above prior to the standard four hour Gr. release 
assay for NK cell activity. The levels of NK cell activity found 
after removal of adherent cells was compared with that found in 
untreated intact PDKG populations from the same pacionts and 
controls.
Results.
Itrom figure 6 it may be seen that the effect of the removal 
of adherent cells from the population of effector cells is to 
increase the level of NK cell activity. The observed increase 
was not as great as that found following carbonyl iron treatment 
nor is it statistically significant. p«rC.03 at the 100:1 E:T 
ratio for the patients group and p-rO.5 for the control group at 
the same E:T ratio. these results are summarised in table 7*
3. Natural killer cell activity against various target cells.
It has been shown that peripheral blood NK cells from an
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Table 6.
0^ of Release
Patient Control
E:T Ratio 100:1 50:1 25:1 100:1 50:1 25:1
Untreated 11.5 9.9 6 .5 27.7 24.9 16.8
Carbonyl iron 
treated 20.2 16.3 10 36.7 32.3 24.2
5I
Mean Cr release during a four hour cytotoxicity assay before 
and after removal of phagocytic cells for patients with AD and 
age and sex matched controls.
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Fifoire 6.
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100:1
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50:1 25:1
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I
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CONTROLS
I
100:1 50:1 25:1
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Mean +SE of chromium release before and after removal of adherent 
cells by incubation in glass or plastic for patients with AD and 
age and sex matched controls.
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Table 7<
fo  ^Or Release
Patient Control
E;T Ratio 100:1 50:1 25:1 100:1 50:1 25:1
Untreated 12.7 7.6 3.7 30.8 21.8 7.6
Plastic/ciass 
Incubâted 15.7 10.2 4.8 34.6 20,6 11.4
5I
Mean Cr. release during a four hour cytotoxicity assay, before 
and after removal of adherent cells, for patients with AD and age 
and sex matched controls.
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individual show varying degrees of activity against different 
target cells (Santoli, et al. 1976). It was decided therefore, to 
investigate whether the difference in M  cell activity observed 
between patients with AD and normal controls was due to 
differences in reactivity against the target cell used, namely 
K^é2, rather than any differences in the lytic ability of the 
effector cells.
Four different target cells were used: BJAB, CCRF-CEM, Molt-I| 
and Namalva. CCRF-CEM and Molt-L are recognised target cells (Phillips 
et al. 19BO: Callewart, et al. 1979)* BJAB and Haus^lva'were included 
due to their availability within this department. Full details of 
these cells were given in table one. Peripheral blood NK cell activity 
was measured in ten patients against each of the target cells in a 
four hour cytotoxic assay. As with previous experiments cells from 
age and sex matched healthy controls were also measured. The ratio 
of males to females, patients and controls, used in each experiment 
wast-
a) BJAB
b) CCRF-CEM
c) Molt-U
d) Namalva
M F
Patients Uî 6 
Patients 3: 7 
Patients 9: ^ 
Patients 3: 7
M F
Controls 3: 5 
Controls 2: .1+ 
Controls 2: 2 
Controls 1: 5
Results.
The results of this experiment showed that the overall 
level of NK cell activity, for both patients and controls, was 
reduced against all four target cells compared with that found
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when K962 was the target. See figures 7 a, b, o, and d. The level 
of NK cell activity of the control subjects remained higher than 
that of the patients, although with BJAB and Namalva, the difference 
was very small, indeed the level of activity was so low for both 
patients and controls that these two target cells might be referred 
to as NK resistant and not suitable as targets. A significant 
difference between the patients and controls was only demonstrated 
with CORF-CEM (p<.0.0$ at 100:1) this was less significant than 
that found with k562 (p<. O.OOU at 100:1).
The sensitivity of the various target cells to lysis by NK cells 
was CCRP-OEM Molt-lr > BJAB > Namalva. and all of these were less 
sensitive than K962, These results are summarised in table 8.
Conclusions.
The above results demonstrate that the methodology used in 
the assay does not account for the varying results obtained by 
other investigators. The extended 18 hour incubation time caused 
an increase in NK cell activity in the patient’s effector cells. 
However, there was also a similar, though lesser, increase in the 
level of activity seen in the control group. The difference 
between the two groups was therefore less following an 18 hour 
incubation as compared with that after four hours but it remained 
statistically significant. One may therefore assume that abnormal 
activation of effector cells is not the cajise of the reduced levels 
of NK cell activity in patients with AD as even with an 18 hour 
incubation the patient's effector cells still do not reach the level
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Figure 7a.
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Mean + SE of chromium release for patients with AD and age and 
®ex matched controls using BJAB as the target.
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Figure 7b.
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57b
Figure 7c.
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Figure 7d.
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Table 8.
io ^^Cr Release
. - _____  ___  . !
Patients Controls
E:T Ratio 
Target Cell 100:1 50:1 25:1 100:1 50:1 25:1
BJAB 3.1 1 .7 1.8 3 .4 2.2 1.1
CCRF-CEM 5 .5 4 .5 4 .2 10.8 9 .3 7 .1
Namalva 1.1 1,1 1.0 1 .4 1 .4 1.1
Molt—4 5 .2 3 .4 2.6 8.8 4 .8 2.2
51Mean Cr Release during a four hour cytotoxicity assay, with 
target cells other than K562, for patients with AD and age and 
sex matched controls.
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of activity of the control subjects.
Removal of phagocytic/adherent cells from the effector cell 
population also caused an increase in the level of NK cell activity 
in both patients and controls. Removal by carbonyl iron treatment 
of the effector population caused a greater increase in activity 
than that by adherence to glass or plastic. Neither of these methods 
closed the gap between the two groups. If there is inhibition of NK 
cell activity in AD then it is unlikely to be due solely to the 
presence of phagocytic/adherent cells.
The third experiment showed that the choice of target cell 
did affect the level of NK cell activity, which, depending on the 
target cell, could result in a highly significant difference, a 
slightly significant difference or no difference at all between the 
patients and controls. However, the level of activity in the controls 
was always greater than in the patients, to a varying degree, with 
BJAB and Namalva proving to be NK resistant targets. This suggests 
that the variation is due to the inherent ability of the target 
cells to resist lysis rather than differences within the effector 
populations. If the difference in NK cell activity was due to 
different specificities within the effector cell population then it 
would be expected that some target cells might be more easily lysed 
by effector cells from individuals with AD than from controls. This 
was not demonstrated.
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Of the parameters investigated none could be said to account 
for the varying results between investigators. The level of M  
cell activity in patients with AD was found to be consistently 
lower than that of the controls throughout this group of 
experiments. The cause of this reduction is unclear but there 
are several possibilities. The reduced levels of effector cell 
function may be due to the disorder itself, reduced numbers of 
effector cells, reduced function in the effector cell population, 
the presence of an inhibitory factor or even the treatment of the 
disease.
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C H A P T E R  F I V E
Sequential study of NK cell activity in patients with AD.
60
Introduction.
NK cell activity was monitored in a group of patients with 
AD sequentially over a twelve month period. NK cell activity of 
normal individuals remains relatively constant over extended 
periods of time (Pross and Baines I982). As AD is a chronic 
relapsing disorder it was of interest to establish whether or 
not NK cell activity correlated with the clinical severity of 
the disorder or whether patients with AD retained a relatively 
stable, albeit reduced NK cell function.
Seven young adults (3 males and 4 females with ages ranging 
from 19 to 30 years, mean age 24) were selected for close follow 
up of their atopic dermatitis. The patients were examined on a 
total of 52 occasions: three patients on six occasions, and one
patient on seven, eight, nine and ten occasions. At each the 
disease activity was assessed by clinical examination of sixteen 
body sites, (figure l) for the six clinical features described 
in materials and methods. The patients were examined by the 
same clinican on each occasion in order that subjectivity be 
kept to a minimum. A peripheral blood sample was taken on each 
occasion for NK cell activity and serum IgE levels. A sample 
from an age and sex matched healthy control was also included.
Results.
The level of NK cell activity of these patients was again 
observed to be very much reduced in respect to the control subjects.
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subjects, 19 .3 vs 32.3 at 100:1, 1U*7 vs 27.6 at 90.1, 9*9 vs 19*9 
at 29:1 (mean NK levels for the duration of the experiment). A 
seasonal variation in the NK cell activity of these patients was 
observed with the lowest values for NK cell activity recorded in the 
period January to March, see figure 8. Over the next three months 
NK cell activity rose towards normal levels. During this time the 
patients also had a relative remission of their dermatitis. The pattern 
in the autumn was less clear though there was some rise in the disease 
activity and the NK cell activity was observed to fall. The patient 
with the highest disease activity also had the lowest NK cell activity. 
The patient with the lowest disease activity (M\7) went into virtual 
clinical remission over the course of the study and her NK cell 
activity was also found to have risen to normal levels. Figure 9 
displays the disease activity of each of the patients throughout the 
study.
NK cell activity was found to correlate with clinical score 
throughout the period of study, at all three effector to target cell 
ratios, in an inverse manner, i.e. the more active the disease 
clinically (the higher the score) the lower the NK cell activity, 
r = -O.i+OO, p<l 0.01.
The group as a whole also showed the recognised relation­
ship between clinical activity and both serum IgE and log IgE
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Figure 8.
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Figure 9.
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level. Two of the patients who showed this relationship most 
clearly are displayed in figure 10. However, IgE and log IgE 
did not show a significant relationship to M  cell activity.
These results are summarised in table 9*
One of the patients, a young man, was discovered to have a 
serious alcohol problem during the course of the study. Inter­
pretation of his results (his NK cell activity was consistently 
high/normal) in the light of his co-existent liver disease was 
impossible, therefore, his results were excluded from subsequent 
analysis.
Conclusions.
This experiment confirmed that reduced amounts of NK cell 
activity are found in individuals with AD. An inverse relation­
ship between NK cell activity and disease activity was demonstrated 
ie, the more active the disease the lower the NK cell activity. 
Seasonal variation in both the level of NK cell activity and the 
disease activity were also shown. As expected no relationship 
between either serum IgE levels or log serum IgE levels and NK 
cell activity was found.
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Figure 10.
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Table 9.
NK oeil activity 
100:1 50:1 25:1 
Clinical Score ”0,4-00+++ “0,4-11+++ —0,405+++
IgE 0.286 0.263 0.220
Log IgE 0,270 0,238 0,163
+++ p 0,01
Correlation coefficients for NK cell activity with clinical 
score, IgE level and Log IgE level for patients with AD,
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CHAPTER SIX
PLUIORESCENT MARKER STUDIES
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Introduction.
The reduced NK cell activity in patients with AD could he 
due to either a quantitative defect of NK cells ie. a reduction 
in the absolute number of effector cells present, or a 
qualitative defect ie. normal numbers of effector cells but with 
reduced activity. The following experiment was designed to 
investigate these possibilities further. The percentage of 
effector cells present in the peripheral blood of patients 
with AD and normal controls was estimated using a fluorescent 
Sandwich technique. Two monoclonal antibodies were used, NNK-1 
(Leu—7) and Leu—11b. The percentage of positively staining 
cells was then correlated with functional activity as measured 
by the standard chromium release assay.
Results.
HNK-1 (Leu-7).
The experimental group consisted of 22 patients with AD (16
female, 6 male) and 2 4  control subjects (12 female, 12 male). The
difference in NK cell activity, as measured by chromium release,
between patients and controls was found to be highly significant
at each of the E:T ratios examined (table lO), p< 0,005 by McLnn. -
test. There was a highly significant difference in the
numbers of HNK-1 (Leu-7) positive cells for the patients as
compared with the normal controls (ll.l vs I7.4) p<  0,005 by
Ma.v\vA - \A/witvva_y -t'est (table 11,). The results of regression
51analysis showed that the line of percentage Cr. release
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Table 10.
ia Cr, Release
Pa-;ient Control
E;T Ratio 100; 1 50:1 25:1 100:1 50:1 25:1
Expt. 1 20.1+2.4 14.9+2 9.5+1.7 35+2.5 30.8+2.7 22.9+2.5
Expt. 2 12.7+1.6 8.2+1.2 3.8+0.6 26.7+2.2 20.7+2.1 13*1+1.6
Meqn +SE of chromium release following a standard four hour cytotoxic­
ity assay for patients with AD and age and sex matched normal controls, 
(Experiment 1 HNK-1, Experiment 2 Leu-llb).
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Table 11.
io Positive staining cells
HM-l Leu-llb
Patient 11+1.1 12.8+1.0
Control 17.4+1.3 14.1+0.8
Mean +SE of percentage positive staining cells using either 
HWK—l(Leu—7) or Leu—11b for patients with AD and age and sex 
matched normal controls.
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against percentage HNK-1 positive cells for the patients had a large 
gradient, 1.39, and a small intercept, ^.6. While a similar line for the 
control subjects had a small gradient, 0.72, and a large intercept, 20.8. 
This suggests that there are two separate lines for patients and 
controls, From figure 11 it can be seen that the patients are clustered 
round the bottom part of the graph whereas the controls are to be 
found further up. This suggests that there are more effector cells 
present in the control population giving rise to greater chromium 
release which supports the hypothesis that reduced NK cell activity 
is due to reduced numbers of effector cells as stained by HNK-1. A 
significant correlation was found between the percentage of HMK-1 
staining cells and chromium release for both the patients and controls. 
For the patient group the correlation was found to be most significant 
at the 100:1 E:T ratio, r= 0.972, pcO.01, than at the 90:1, r=0.907, 
p< 0.02, or the 29:1, r= 0.1|73, p-C 0.09* The correlation for the 
control subjects was not significant at the 100:1 E:T ratio but was 
found to be significant at the 90:1, r= 0.i|97. p< 0.02 and at the 
29:1, r= 0.486, p<0.09.
Leu-11b.
As HNK-1 has been shown to be reactive with most but not all 
NK cells (Lanier, et al. 1983) the above experiment was repeated 
using Leu-11b which is said to be more specific than HNK-1. The 
experimental group consisted of 30 patients with AD (22 female, 8
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Figure 11,
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male) and 17 controls (7 female , 10 male). The difference in NK
cell activity between patients and controls was again found to be
highly significant, p< O.OQ^ by Mann-Vhitney test, at each of the
E:T ratios examined (table 10). The number of Leu-lib positive cells
was not significantly different in the patients with AD compared to
the controls, (12.8 vs lU*l) p<0.3 by Mann-Whitney test (table 11).
The results of regression analysis again showed that the line of 
1^percentage Or. release against percentage Leu-11b positive cells 
for the patients had a large gradient, 0*6, and a small intercept,
3.2. While a similar line for the controls had a small gradient, 0.16, 
and a large intercept, 23.1. These results also suggest that there are 
two separate lines for patients and controls. IVhen the results are 
displayed graphically,as in figure 12, it can be seen that there is 
not as much clustering as was found with HNK-1. The different values 
obtained for gradient and intercept for patients and controls 
coupled with the observations of the lack of clustering and the 
similar numbers of Leu-lib positive staining cells suggests that 
there is no difference in effector cell numbers, that would account 
for the differences in activity of patient and control effector cells, 
rather there are two sets of kinetics involved.
Unlike HNK-1 no correlation hfa.'S found between the percentage 
of Leu-lib positive staining cells and activity at any of the E:T 
ratios for both patients and controls.
68
Figure 12 ,
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Conclusion.
The results of this experiment have shown that there is a 
correlation between the number of MK-l”^ cells and percentage 
chromium release but not between Leu-llb^ cells and percentage
chromium release. A significant difference in the number of
+ +HNK—1 but not Leu-llb cells was found between patients
and controls. The results of regression analysis for both
monoclonals suggests that the kinetics of the patients' response
are different fhom those of the normal controls. As Leu—11b is
said to be a more specific monoclonal antibody than HNK-1 these
results suggest that the reduction in NK cell activity in
patients with AD is more likely to be due to a functional difference
in the effector cells between patients and controls. The defect in
the patients' effector cells may be an inability to bind the
target cells or ineffective killing or a poor recycling
capability. There are several possible underlying causes of the
reduced function. The effector cells could be inhibited by the
presence of a factor in the circulation of these patients caused
by the underlying condition itself, or the treatment of the
disease by topical steroids could effect the function of the NK
cells.
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CHAPTER SEVEN.
Investigation of serum inhibitory factors,
70
Introduction.
The presence of inhibitory factors in the circulation of 
patients with AD could account for the low levels of NK cell 
activity despite the presence of normal numbers of Leu—11b 
positive staining cells. Nair and Schwartz (1982) have reported 
the existence of soluble- factors, produced by unstimulated 
lymphocytes, that are able to inhibit natural killing. It has 
also been reported by Barrett et al. (1982) that preincubation 
or assaying of effector cells in medium containing maternal or 
neonatal serum results in inhibition of cytotoxicity. In I983 
Sibbitt et al. showed that serum from patients with SLE could 
cause up to 30^  ^inhibition of cytotoxicity. It has been 
observed that the chemotactic responses of neutrophils from 
patients with AD are reduced and that this reduction is due to 
the presence of a serum derived inhibitory factor (Rogge and 
Hanifin. 1976 : Snyderman, et al. 1977). The degree of im­
pairment of chemotaxis was also found to correlate with the 
severity of the disease and improved with clinical remission 
(hanifin, et al. 198O). It is therefore possible that a similar 
factor may be the cause of the reduced levels of NK cell activity 
seen in atopic dermatitis.
The following study was designed to examine the effects on 
NK cell activity of incubating effector cells from patients with 
AD and age and sex matched controls in medium supplemented with
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iCffo autologous serum, ICffo homologous serum or lOfo foetal calf 
serum (PCS).
NK cell activity was assessed in ten patients with atopic 
dermatitis and ten age and sex matched healthy controls. Three 
different protocols were used in this experiment, these were:-
1. Standard four hour cytotoxicity assay in 
supplemented medium.
2. Eighteen hour cytotoxicity assay in 
supplemented medium.
3. Overnight incubation of effector cells 
in supplemented medium followed by a 
standard four hour cytotoxicity assay, also 
in supplemented medium.
■Results.
Four hour cytotoxic assay in supplemented medium.
From figure 13 it can be seen that the NK cell activity of 
the controls is significantly higher than -that of the patients 
in all three groups p«=:Q.005. The incubation of patients effector 
cells in medium containing 10^ control serum resulted in a slight 
and insignificant increase in NK cell activity compared with the 
amount of activity found following incubation of cells in medium 
supplemented with 10}t autologous serum. The converse was also 
found to be true, ie. incubation of control effector cells in
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Fiffure 13.
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medium containing IC^ patient serum resulted in a slight, and 
statistically insignificant^decrease in NK cell activity compared 
with control effector cells incubated in medium containing 10^ 
autologous serum. Incubation of effector cells in medium 
supplemented with lOfo FCS resulted in a slight enhancement of 
NK cell activity for both the patients and the controls. There 
was however, no significant difference between the three groups 
ie. those incubated in medium supplemented with IQffo autologous, 
IC^o homologous or ICffo FCS. These results are summarised in 
table 12.
As no significant differences were seen in effector cell 
activity following a four hour assay it was decided to extend 
the incubation time.
Effect of an 18 hour cytotoxic assay in supplemented medium.
The results of this experiment were very similar to those 
found after a four hour incubation although the percentage 
release was much higher, see figure 14, following an 18 hour 
incubation. The percentage difference, approximately 2jfo 
between the patients and controls remained the same (statistical 
significance, P<0.005). These results are summarised in table 
13.
As an 16 hour incubation in the presence of labelled target 
cells showed an increase in the activity of both patient, and
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Table 12.
io of ^^Cr Release
Autologous Homologous FCS
E:T Ratio 100:1 50:1 25:1 100:1 50:1 25:1 100:1 50:1 25:1
Patient 9.6 6 .4 4 .1 11.0 7 .4 4 ,9 11.1 8.6 4 .5
Control 3 3 .4 26.6 18 .3 32 .4 25 .6 16.9 31 .2 25.6 17.3
51
Mean Cr. release for patients with AD and normal controls during 
a standard four hour cytotoxicity assay in supplemented medium.
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Figure 14.
% Cr 
RELEASE
6 0 “
4 0  -
20-
Autologous
I II
Homologous
I i
F.C.S.
^  Patient 
I I Control
100:1 50 :1  25:1 100:1  5 0 :1  2 5 :1
E:T RATIO
100:1  5 0 :1  2 5 :1
Mean +SE of cliromium release following an l8 hour cytotoxicity 
assay in supplemented medium for patients with AD and age and 
sex matched controls.
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Table 13
fo ^^Gr Release
Autologous Homologous PCS
E;T Ratio 100:1 50 :1 25:1 100:1 50 :1 25:1 100:1 50 :1 25:1
Patient 35.6 28 .3 2 3 .8 36.5 28 .6 22.2 36 .4 34.7 26 .9
Control 58.7 5 4 .4 4 0 .0 59 .5 5 2 .4 41 .1 58 .9 53.9 42 .9
51Mean Cr. release for patients with AD and normal controls during 
an 18 hour cytotoxicity assay in supplemented medium.
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control, effector cells. It was then decided to examine the 
effect of preinouhation of the effector cells overnight in 
supplemented medium prior to a standard four hour cytotoxicity 
assay.
Effect of prior 18 hour incubation in supplemented-medium on the 
results of a standard four hour cytotoxic assay.
Prior incubation of effector cells in supplemented medium 
had no significant effect on the NK cell activity of either the 
patients or the controls, as seen in figure I5. As in the 
previous experiment the level of NK cell activity of the control 
subjects remained higher than that of the patients. However, it 
was observed that effector cells (patients and controls) incubated 
in medium supplemented with IC^ PCS had a very much higher level 
of NK cell activity than those incubated in medium containing 
either 10^ autologous or homologous serum. Indeed the amount of
51 Gr. release for patientb effector cells, preincubated in medium 
containing 10^ PCS, reached levels of activity similar to those 
from control subjects whose effector cells had been incubated in 
medium supplemented with either 10^ autologous or IC^ homologous 
serum. However, similar increases in NK cell activity were also 
seen in the controls following I8 hour preincubation in medium 
supplemented with 10^ PCS.
These results are summarised in table I4.
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Figure 15.
RELEASE
4 5 -
3 5 -
25 -
5 -
Autologous
M  Patient 
I I Control
I
Homologous F..C.S*
100:1 50:1 25:1 100:1 50:1 25:1
E:T RATIO
100:1 50:1 25:1
The effect of overnight incubation of effector cells from patients 
with AD and age and sex matched controls in supplemented medium 
on the mean +SE of chromium release following a standard four hour 
cytotoxicity assay.
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.Table 14.
o^^ 'Cr. Release
Autologous Homologous . PCS
E:T Ratio 100:1 50:1 25:1 100:1 50 :1 25:1 100:1 50:1 25:1
Patients 15.3 12 .2 9.1 15.6 14 10.5 2 4 .8 23 .0 17 .2
Controls 32.1 26 .8 1 6 .8 31.2 2 5 .8 14.5 4 0 .7 43.2 34.6
Mean Cr. release for patients with AD and normal controls during 
a standard four hour cytotoxicity assay following l8 hour incubation 
of patient and control effector cells in supplemented medium.
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Conclusions.
The findings of these experiments failed to show the 
presence of a serum inhibitory factor in AD that could be 
responsible for the reduction in NK cell activity. They do, 
however, confirm both the reduction seen in the NK cell activity 
of these patients and the effect of an 18 hour cytotoxicity assay 
on the level of activity observed (compare figure 4 with figure
14).
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CHAPTER EIGHT
The effect of topically applied steroids on the NK cell 
activity of normal subjects.
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Introduction.
Topical steroids form the main course of treatment in AD, 
systemic steroids are used hut only very rarely. Systemic 
steroid therapy has been shown to depress peripheral blood NK 
cell activity (Parrillo and Fauci. 1978). It is possible that 
systemic absorption of topically applied steroids may be the cause 
of the reduction seen in NK cell activity. The following exper­
iment was designed to investigate the effect of topical steroid 
application on the peripheral blood NK cell activity of normal 
volunteers.
Ten normal healthy volunteers were used in this study, five
female and five male, their ages ranged from 19 years to 31 years.
All of the volunteers had no past personal or family history of 
atopic disease. Within the group of female volunteers one had
a history of cold urticaria and one had contact sensitivity to
jewellery. Within the male groùp one had acne and one had a 
past history of urticaria. These details are summarised in 
tables 15 and l6.
Results,
Peripheral blood NK cell activity was found to have fallen 
within the group as a whole as early as day 3, see figure 16,
This decrease reached a statistically significant level by day 'J: 
pc0,05 at the 100:1 ratio using the paired t-test. The level of 
NK cell activity then rose slowly until base line levels were again 
achieved by day 22.
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Table 15.
Study Group.
10 Normal Volunteers.
Male Female
Number 5 5
Age (Mean) 26-31 (2?.6) 19-31 (23.O)
Details of Study Group.
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Table l6.
t^iidy Group.
Past Medical History-
Male 1 acne
1 Urticaria (lO years ago)
Female 1 cold urticaria 
1 contact dermatitis (earrings)
Past medical history of study group»
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Figure 16.
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The effect of topical steroid application on the NK cell activity 
of normal volunteers as shown by the mean +SE of chromium release 
following a four hour cytotoxicity assay.
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If the two groups are analysed separately, ie, males and 
females (figure 17), it may be seen that the NK cell activity 
of each group behaves slightly differently. In the female group 
NK cell activity is seen to drop through the period of application 
of the steroid ointment. It then rises slightly and drops again 
at day fifteen.
In the male group, however, the NK cell activity reaches its lowest 
level by day 3 and stays at this lower level during the period 
of. application after which it rises to base line levels. There is 
also a slight dip around day 18, similar to the female group, but 
it is not as pronounced.
Effect, of base alone.
To confirm that the observed reduction was due to the effect 
of the topically applied steroid and not to some other factor or 
component of the ointment, the experiment was repeated using the 
base for the steroid. Four of the original group of volunteers 
were recruited to repeat the study. The NK cell activity of these 
four subjects was then compared following the application of the 
base alone.
After an initial slight rise the activity was observed to 
fall (figure 18). The drop in activity was, however, not as 
large as that found when the steroid was used. It was also found 
that the difference between these two groups was not statistically 
significant. The difference between the two groups can be more
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Figure 17.
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The effect o f  topical steroid application on the NK cell activity 
of the male and female volunteers as shown by mean +SE of chromium 
release following a four hour cytotoxicity assay.
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Figure l8.
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The effect of topical steroid ointment base alone on the NK cell 
activity of normal volunteers as shown by mean +SE of cliromium 
release following a four hour cytotoxicity assay.
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clearly seen in figure 19. This graph was made by subtracting 
the baseline NK cell activity, before the subjects applied any 
base/bintment, from that found on sampling days and plotting this 
difference against time.
Conclusion.
The results of this experiment would suggest that NK cell 
activity of normal healthy individuals may be reduced following 
the application of topical steroids. However, they did not cause 
the NK cell activity of these individuals to fail to levels seen 
in patients with AD, Therefore, it would appear that topical 
steroids are not the only cause of the reduced levels of NK cell 
activity,
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Figure 19.
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Change in NK cell activity of normal volunteers following the 
application of a topical steroid or base alone as shown by mean 
' of chromium release following a four hour cytotoxicity assay.
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Chapter Nine
Tha in vitro, effect of adrenaline^ noradrenaline. 
'betamethasone and histamine acid phosphate on the 
NK cell activity of normal controls.
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Introduction.
Stress is known to be a factor in causing patients with AD 
to flare i.e. for the disease to become active. As the physiological 
effects of stress are mediated by the products of the adrenal glands 
it was decided to investigate the effect of adrenaline and 
noradrenaline on NK cell activity in vitro. Histamine was also 
investigated, because of its primary role in allergic reactions. 
Betamethasone was included to ascertain whether or not a greater 
reduction in NK cell activity could be achieved by steroid treatment 
in vitro compared with that induced in vivo by the application of 
topical steroids (chapter eight). The effect of these four agents 
on NK cell activity was assessed using PBMC from six normal subjects, 
two female and four male in each group of experiments.
The results are expressed as percentage inhibition. This was 
achieved as follows. The controls (without the agent) were taken as 
100% chromium release, and the percentage isotope release from the 
groups that had either of the four agents present was subtracted from 
100%, the balance was therefore the percentage inhibition.
Results.
The effect of preincubation of effector cells for one hour with 
various concentrations of adrenaline, noradrenaline, betamethasone and 
Histamine acid phosphate on the NK cell activity of normal subjects.
Adrenaline, noradrenaline and betamethasone were found to 
inhibit NK cell activity at each of the EîT ratios in a dose 
dependent manner following a one hour preincubation. Figure 20 a, b, 
and c. (These figures show only the 100:1 ratio). .
Histamine on the other hand, was found to have slight 
stimulatory effect on the NK cell activity of the normal subjects in a
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Figure 20 a.
% Inhibition
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10" ^  10" ^  10" ' '  10" ^
CONCENTRATION
Mean +SE inhibition of NK cell activity following preincubation 
for one hour of effector cells with adrenaline at concentrations 
of 0.05 mM (10“^) to O.0OOO5 mM ( 10“^ ) E:T ratio 100:1 
* P^o.005, *** P.“=0.05, 10"5 N.s.
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Figure 20 b<
% Inhibition
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10“2 10“3 10"* 10'S
CONCENTRATION
Mean +SE inhibition of MK oeil activity following preincubation
for one hour of effector cells with noradrenaline at concentrations 
of 0.02 mM (10"2) to 000002 m  (lO"^) E:T ratio 100:1
*p<: 0.005, ** pCO.02, lO”  ^NS.
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Pleure 20 c.
% Inhibition
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NS
10-
r-2 i - 3
CONCENTRATION
Mean +SE inhibition of NK oeil activity following preincubation 
for one hour of effector cells with betamethasone at concentrations 
of 0.07 mï4 (10”2) to 0.00007nM (lO”^) E:T ratio 100:1 
* pC0,005, . p<0.05, 10”  ^NS. .
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negative dose dependent manner i.e. the lower the concentration 
the higher the M  cell activity. See figure 20 d.
Addition of adrenaline in ten fold dilutions ranging from
O.O^ mM to O.0OO5mM resulted in 41^ inhibition (at 0,05 n#) to about
Vjo enhancement (at 0,0005mM). Ten fold dilutions of noradrenaline
ranging from 0.02mM to 0.,0002mM resulted in 54 (at 0.02mM) to 10
percent inhibition (at 0..00002mM), addition of betamethasone in
concentrations from 0.07mM to 0.00007mM resulted in 35 (at Cl07mM)
to 10 percent (at Q00007mM) inhibition. The percentage increase
in NK cell activity following preincubation with histamine ranged
from about 1^ at the 0.03 mM concentration to about 8^ at the
0.00003mM concentration. The levels of inhibition for adranaline,
noradrenaline and betamethasone were found to be statistically
“4significant up to the 10 concentrations ie. p-=i0,005 at the 
100:1 ratio for the highest concentration to p < 0.05 at the lO”^ 
concentration, although at the lowest concentration the level of 
inhibition was not significant. The percentage increases in NK 
cell activity following preincubation with histamine acid phosphate 
however, were not found to be significant. The results of this 
experiment are summarised in table 17.
NK cell activity of normal subjects following the addition of 
adrenaline, noradrenaline, betamethasone and histamine acid 
phosphate at the start of a standard four hour cytotoxicity assay.
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Table 17.
% Inhibition
Concentrât ion io”2 10”^ io”4 10”5
D Adrenaline 41.3 34.1 23.6 -0.7
R Noradrenaline 54.2 43.3 20.8 9.0
U Betamethasone 35.8 26 .7 13.4 9.6
G Histamine Acid 
Phosphate -0.35 -0.93 "1.5 -7.7
Percentage inhibition of NK cell activity at the 100:1 E:T ratic 
following one hours preincubation with adrenaline, noradrenaline, 
betametheesone and histamine acid phosphate at various concentrations 
prior to a standard four hour cytotoxicity assay.
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Figure 20 d.
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CONCENTRATION
Mean +SE inhibition of NK cell activity following preincubation 
for one hour of effector cells with histamine acid phosphate at 
concentrations of 0,03 mM (lO to 0.00003mM (lO 
E;T ratio 100:1 
* N.S.
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The above experiment was repeated with two alterations to 
the method. Firstly, the different agents were added at the 
beginning of the assay with the target cells and secondly they 
were added at their highest concentrations. When the agents 
were added with the target cells a much greater inhibition 
resulted than that which was found following one hours pre- 
incubation. See figure 21. The percentage inhibition in­
creased by about 25% for adrenaline (p< 0.005), 15% for nor­
adrenaline (p< 0.005), 15% for betamethasone (p<0.005) and 
16% for histamine (p<0.05). These results are summarised in 
table 18.
The effect of a four hour preincubation of effector cells with 
adrenaline, noradrenaline, betamethasone and histamine acid 
phosphate on the NK cell activity of normal subjects.
From the results of the previous experiments it was decided 
to investigate the effect of a longer preincubation of effector 
cells with these agents at their highest concentrations prior to 
setting up the cytotoxic assay.
Longer preincubation with adrenaline, noradrenaline or 
betamethasone resulted in lower levels of inhibition of NK cell 
activity than those seen following either one hours preincubâtion 
or addition of these agents with the target cells. See figure 22. 
It was also observed again that histamine caused a slight increase 
in the level of NK cell activity. The level of enhancement
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Figure 21
% Inhibition
80“
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50"
40'
30"
20"
10-
NORADRENALINE
ADRENAUNE
BETAMETHASONE
HISTAMINE ACID 
PHOSPHATE
Mean +SE inhibition of NK cell activity following the addition of 
adrenaline 0.05 noradrenaline 0,02 rnM, betamethasone 0.07 id/I and 
histamine acid phosphate Q.03 mM at the start of a standard four 
hour cytotoxicity assay.
E:T ratio 100:1 * p <  0.0005 p <  0.05
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Table 18
Drug % Inhibition
Adrenaline 67.0
Noradr enaline 72.1
Betamethasone 57.4
Histamine Acid 
Phosphate 15.4
Percentage inhibition of NK cell activity at the 100:1 E:T ratio 
following the addition of adrenaline, noradrenaline, betamethasone 
and histamine acid phosphate at a concentration of 10  ^at the start 
of a standard four hour cytotoxicity assay.
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Figure 22,
% Inhibition
30"
20"
10"
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-10“
BETAMETHASONE
ADRENALINE ^OR- 
T  ADRENALINE
HISTAMINE ACID 
PHOSPHATE
Mean +SE inhibition of NK cell activity following a four hour pre­
incubation of effector cells with adrenaline at 0,05 mM, noradrenaline 
0.02 mM, betamethasone OJT{ mM and histamine acid phosphate mM 
prior to a four hour cytotoxicity assay.
E:T ratio 100:1 * p<0.03 ** p<0.2 ***p<0.05
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following a four hour preincubâtion was as great as that found 
following one hours preinoubation with histamine at the lowest 
concentration. The inhibition caused by adrenaline, and beta­
methasone was not as significant as was found previously p < 0.05, 
and that caused by noradrenaline was not significant. The 
enhancement seen following preincubation with histamine was only 
slightly significant, p< O.O5. These results are summarised in 
table l9.
Conclusions.
From the results of this experiment it may be seen that 
adrenaline, noradrenaline, betamethasone and histamine have a 
dose dependent effect on NK cell activity in vitro. Adrenaline, 
noradrenaline and betamethasone cause inhibition of the response 
whether they are added with the target cells or are preincubated 
with the effector cells for either one or four hours prior to 
setting up the assay. It was observed that the longer the 
preincubation was the smaller the resulting inhibition.
Histamine, on the other hand, caused a slight enhancement following 
a one hour preincubation with the effector cells, but in a 
negative dose dependent manner, i.e. the lower the 
concentration the greater the enhancement, A four hour 
preincubation with histamine, at the highest concentration 
resulted in enhancement as great as that found following the one 
hour preincubation at the lowest concentration. Histamine was
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Table 19
Drug % Inhibition
Adrenaline 17.1
Noradr enaline 13.9
Betamethasone 23.5
Histamine Acid 
Phosphate -9.0
Percentage inhibition of NK cell activity at the 100:1 E:T ratio 
following a four hour preincubation with adrenaline, noradrenaline, 
betamethasone and histamine acid phosphate at a concentration of 
10  ^prior to a standard four hour cytotoxicity assay.
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found to cause inhibition of the NK cell response only when added 
at the same time as the target cells.
It would, therefore, appear that the effect of these agents is 
only transient and that following addition to the effector cell 
population they are metabolised, hence the reduced effect following 
the preincubâtions. Histamine on the other hand, appears to have 
its enhancing effect once it has been metabolised.
These results indicate that at the concentrations used these 
agents have a very significant effect on NK cell activity in 
vitro. However, whether or not they have the same effect in vivo, 
cannot be determined from these results. Adrenaline and noradrenaline 
were both used at pharmacological rather than physiological doses 
and the dose responsiveness of these two drugs suggest that at 
physiological concent-rations they would have no inhibitory effect 
on NK cell activity.
The results also show that very low concentrations of 
betamethesone can inhibit NK cell activity in vitro therefore, 
one may assume that if sufficient amounts of topical steroid 
could penetrate the skin then it could cause a quite marked 
reduction in NK cell activity in vivo.
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CHAPTER TEN
DISCUSSION
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Abnormal immunological functions, both humoral and cellular, 
have been reported in patients with atopic dermatitis. Reports of 
altered natural killer cell function have been conflicting. Some 
groups report that NK cell activity, in vitro, against tumour 
cell targets is reduced (Kusiami and Trentin. 1982) while 
others have found normal or raised levels of activity (Viander et 
al. 1982: Strannegard and Strannegard 198O). In addition raised
levels of activity against autologous and allogeneic skin 
fibroblasts have been reported (Leung et al. 1982).
The NK cell activity of patients with AD, as measured in 
this laboratory, was found to be very significantly reduced 
compared to those of age and sex matched healthy controls. This 
finding raises two major points of discussion. Firstly, other 
workers have found normal/high NK cell activity against tumour 
cell targets (Viander et al. 1982: Strannegard and Strannegard
1980). This discrepancy could be due to variation in the 
patients selected or differences in the methods used to assay for 
NK cell activity, and I propose to discuss these first. Secondly, 
possible causes for the reduced NK cell activity in AD are 
investigated in a series of experiments and these are considered 
in the second part of the discussion.
Viander et al, (1982) found that the NK cell activity of a 
group of 12 male patients with AD was slightly higher than that
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of the control group. The same incubation time (4 hrs)^ and the 
same target cell (K562) were used in their study as were used in 
experiments in this thesis. On close examination of the data on 
the patients they assessed it can be seen that one had bronchial 
asthma as well as AD. The NIC cell activity of this individual was 
8 33 .3 lytic units,this was approximately seven times higher than 
that of the next highest patient and IO4 times that of the 
lowest. It has recently been reported that the NK cell activity 
of individuals with asthma is significantly higher than 
that of normal healthy controls (Timonen and Stenius-Aarniala. 
1985). It would appear that the overall level of NK cell 
activity for the group of patients was pushed up because of this 
one individual.
Strannegard and Strannegard (1980) also found increased NK 
cell activity in a group of atopic children compared with normal 
age matched controls. All of the subjects were atopic having 
asthma, allergic rhinitis and/or atopic dermatitis but the number 
of each is not stated. This study was looking at atopy in a 
general sense and it is possible therefore,that the level of NK 
cell activity of the subjects with asthma was causing the overall 
group level to be elevated as in the study by Viander et al. It 
was also found that within the patients examined in this study 
those with active asthma as well as AD had a higher NK cell 
activity than those with a past history of asthma which had been 
inactive for some time.
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Another patient variable is alcohol consumption. Saxena 
et al. (1980) found increased levels of NK cell activity in a 
group of 32 alcoholics. One patient in this study was found to 
have an alcohol problem and his NK cell activity was consistently 
high/normal in spite of his atopic dermatitis. Patient selection 
could therefore 'stffect the outcome of NK cell assays, however, 
differences in the laboratory methods might also affect the result 
of NK cell assays.
There were several differences in the assay methodology as 
used in this study and those of Viander et al. and Strannegard 
and Strannegard, namely the length of incubation, removal of 
macrophages and the target cell used. Each of these parameters 
was examined in order to exclude the possibility that the observed 
differences in NK cell activity between patients and controls was 
due to differences in assay technique.
Increasing the length of incubation of effector cells with 
target cells to I8 hours, instead of four, resulted in an 
increase in NK cell activity for the patients. However, the 
activity of the effector cells from the controls also increased 
during the longer incubation and the difference between the 
patients and controls wqs maintained. With increased incubation 
time one would expect that, if defective activation of the 
patient's effector cells was the cause of the reduced NK cell 
activity, the patients would achieve the same level of activity
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as the controls. The fact that the activity of the patients did 
not attain the same level as the controls, or indeed, reduce the 
difference, suggested that the reduced NK cell activity was not 
due to differences in activation of effector cells between patients 
and controls* The observation that the chromium release increases 
during this longer incubation suggests that the patient's effector 
cells are able to kill their targets but that the low levels seen 
in atopic dermatitis are due to a cause other than a defect or 
deficiency in effector cell activation, eg. reduced numbers or 
reduced functional ability of effector cells. The results of studies 
of effector cell numbers with function would suggest that thejba is in 
fact a qualitative abnormality in patient's effector cells. Strannegard 
and Strannegard (198O) found that NK cell activity was increased in 
atopic patients following an 18 hour incubation, however, they used a 
different target cell, P3HR1, and the difference only reached 
significance in a subgroup of older children. Also it should be pointed 
out that 18 hour assays are unreliable due tm the variability in 
spontaneous release over long incubation times.
Macrophages and monocytes in the effector population have 
been shown to inhibit the NK cell response (jondal, et al. I982), 
Melewicz et al. (198I a and b). have reported both increased 
numbers of Fc-IgE receptor bearing monocytes and enhanced 
monocyte-IgE dependent killing in atopic disorders. Jensen et al.
(I98I+) have also shown that the addition of autologous monocytes 
to the cytotoxic assay reduces NK cell activity. It is therefore 
conceivable that there is an in vivo activation of monocytes 
during acute episodes of AD and that effector cell-monocyte
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interaction may cause the reduction in NK cell activity in 
patients with AD. As Viander et al. (1982) found almost normal 
NK cell activity in their study it was of interest to examine the 
effect that removal of macrophages and monocytes, by the two 
methods available, glass/plastic adherence in the case of Viander 
et al. and carbonyl iron ingestion in the case of Lever et al. 
(1984), might have on the outcome of an NK assay.
Removal of macrophages and monocytes increased NK cell
activity although the NK cell activity of the patients remained
51lower than the controls. The levels of Gr. release for the 
patient's effector cells almost doubled while that for the 
controls went up by about 30% following carbonyl iron treatment. 
Depletion by adherence to glass or plastic also resulted in an 
increase in NK cell activity for both groups; this increase, however, 
was not as great as that observed following carbonyl iron treatment. 
The control NK cell activity remained significantly greater than 
that of the patients, it is therefore unlikely that reduced NK 
cell activity in AD is due to effector cell/monocyte interaction 
following activation of the monocyte population as suggested by 
Jensen et.al. (1984) although it may be a contributory factor.
The third difference in methodology to be investigated was 
the use of alternative target cells to K562 in the standard four 
hour assay. Phillips et al. (1980) published results which
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suggested that M  cells may he a heterologous population with 
suhpopulations of cells which recognise different antigenic 
specificities on target cells. It is therefore possible that in 
AD there is a deficiency in one cr more subpopulation(s) of M  
effector cells which could account for the different levels of 
activity that have been reported in studies where different 
target cells have been used, Strannegard and Strannegard (198O) 
found raised NK cell activity in a group of atopic children using 
a Burkitt's lymphoma, P3HR1, as the target.
Four target cells were tested on both patients and controls, 
the overall NK cell activity was reduced against all four of the 
targets compared to that found when K$62 was the target. The 
range of activities observed was, CCRF-CEM> Mo It-4 > Namalva>
BJAB. Only CCRF-CEM gave a significant difference between the 
patients with AD and the controls by Student’s t-test. Although 
the ether three cell lines showed no significant difference 
in activity between the patients and the controls the activity of 
the control effector cells was still greater than that of the 
patients. It is possible that had larger groups of patients and 
controls been used greater differences would have been found. The 
cell lines which proved to be the least sensitive as targets were 
the two B-cell lines, both of which have immunoglobulin, IgM, on 
their surface. It is possible that this surface immunoglobulin 
prevents the NK cell from binding and so protects the cell from 
lysis. It is also interesting to note the low level of activity
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against Namalva, a Burkitt's lymphoma derived cell. This compares, 
with the level of activity found by Strannegard and Strannegard 
(1980), they used another Burkitt's lymphoma, P3HR1, as the target. 
They found that NK cell activity was higher in the atopic group 
than in the control group, 10% as against 7%, however this difference 
only reached significance in a subgroup of older children.
The results obtained with the four alternative target cells, 
CCRP-CEM, Mclt-4, Namalva and BJAB, may be explained in the light 
of findings by Hudig et al. (1981) who found that it was possible 
to increase the sensitivity of a "slow" NK target cell, ie, one 
that has a long lag phase before lysis occurs by preincubating 
it with an inhibitor of protein synthesis. Some target cells may 
actively resist NK lysis tlirough the use of self repair mechanisms 
which would keep the membrane intact. Support for this theory 
has come from the results of a study by Kunkel and Welsh (1981) 
who showed that the treatment of NK resistant target cells with 
metabolic inhibitors renders them sensitive to lysis. If tumour 
cells do have a self repair mechanism then it is possible that what 
is thought to be differences in specificity on the part of the 
effector cell may in fact be differences in the self repair ability 
on the part of the target cell. Roder et al. (l979) showed that 
although NK cells carried unique specificities there were widespread 
crossreactions between target structure complexes suggesting that 
NK cells are to some extent polyspecific while having heterogeneity 
in the recognition structure. These results supported the earlier
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work of Ortaldo et al. (1977) who showed that thirteen out of nineteen 
cell types, including fresh tumour cells (unrelated to the target 
cell), cryopreserved cells, normal lymphocytes and human fibroblasts 
could inhibit NK cell activity when added to a cytotoxic assay.
These two observations suggest that the differences observed in 
sensitivity to lysis by target cells may indeed be due to the 
active resistance of the target cell rather than the hetrogeneity 
of the effector cell. A. further method of self protection of the 
target cell might be its ability to release prostaglandins.
Droller et al. (1978) showed that if prostaglandin production by 
the target cell was inhibited then there was an increase in the 
effector cells activity.
Active resistance, along these lines, would explain the 
results obtained with CCRF-CEM, Molt-U, Namalva and BJAB. The NK 
cell activity of patients with AD is significantly reduced against 
K562, if this reduction is due to a defect or inhibition of effector 
cell function then one would expect that no matter what target cell 
type was used the activity of the patient^ effector cells would be 
lower than that of the controls. This is in fact the case although 
in seme instances that difference was only very slight* It is 
clearly important to use the most sensitive target cell possible 
otherwise differences in effector cell activity in different 
populations may be overlooked. The results also indicate that 
Namalva and BJAB are unsuitable as NK targets.
9h
The main points of this first part of the discussion are:-
1, Patient selection may influence the outcome of
NK cell assays because of the variability of 
NK cell activity in other atopic disorders, 
such as asthma and the influence of other 
factors such as alcohol.
2. Differences in NK cell activity between patients
with AD and controls are not due to differences
in assay methodology.
The above results suggest that the difference in NK cell 
activity between patients with AD and normal controls is a 
genuine one and not due to differences in assay methodology. It 
was therefore necessary to evaluate other possible causes for this 
reduction. The first possibility to be investigated was that the 
disease itself was the cause of the reduced NK cell activity in 
patients with AD.
A sequential study of the NK cell activity of a group of 
patients with AD revealed a correlation between disease severity 
and NK cell activity. That is, the mere active the disease the 
lower the NK cell activity. This is in agreement with the 
observations of Hanifin et al. (1980) who reported that the 
degree of impairment of other cellular functions, the chemotactic 
response of neutrophils, of patients with AD correlated with the
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clinical severity of their disorder. A seasonal variation in the 
NK cell activity of these patients was also observed with the 
lowest values being recorded in the period January to March. Over 
t^e next three months NK cell activity was found to rise towards 
normal levels and during this time the patients also had a relative 
remission of their dermatitis. There was a rise in disease 
activity in the autumn and the NK cell activity was observed to fell. 
One patient went into virtual clinical remission over the course of 
the study and also showed a gradual improvement in her NK cell 
activity. This improvement took from June to December. This 
may reflect thé time taken for the pool of existing inhibited or 
defective effector cells to be replaced with normal effector cells.
The observation- that NK cell activity varied with clinical 
severity suggested that the disease itself caused the reduction in 
NK cell activity. This could be a quantitative or a qualitiative 
defect, ie, it is possible that there are reduced numbers of 
effector cells present in the circulation of patients with AD, 
alternatively, normal numbers of cells could have reduced function. 
This was investigated in the next group of experiments.
Two different monoclonal antibodies were used to estimate 
the numbers of effector cells, HNK—1 (Leu-7) and Leu-llb. When 
numbers were correlated with function, as measured by chromium 
release, conflicting results were obtained.
H h
The results obtained with ffpEK-l (Leu-?) showed a correlation
+between activity and the numbers of HNK-1 cells for -both patients
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and controls. This suggested that the reduction in the activity 
was due to fewer effector cells in the circulation of the patients.
On the otherhand^Leu-llh showed no correlation between numbers of 
effector cells and functionvwhich suggested that the defect was due 
to a difference in the functional ability of the effector cells. 
Regression analysis of the curve of percentage positive cells Vs. 
chromium release gave similar results for both monoclonals, ie. the 
patients curve had a large gradient and a small intercept while the 
curve for the controls had a small gradient and a large intercept. 
This suggested that there were either two sets of different kinetics, 
for patients and controls, or that they were on the same curve with 
the patients falling on the lower half of the curve and the controls 
higher up. On further examination of the curve produced with the 
results of using M K “1 it may be seen that there is a clustering of 
patients and controls with the patients falling in the lower quarter 
of the graph and the controls in the higher quarter, Whereas with 
Leu-llb there is no clustering of patients or controls. Therefore 
the results using HNK-1 suggest a quantitative defect while those 
obtained with Leu-11 suggest a qualitative abnormality. The
question then arises; which is correct?
It has been shown that HNK-1 does not stain all NK cells
(Lanier et al. 1983) and is therefore less specific that leu-llb.
One may therefore assume that the results obtained using Leu-11 
are most likely to be more accurate than those obtained using 
HNK-1. This coupled with the results of the regression analysis
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would suggest that there is no difference in the numbers of 
effector cells present in both patients with AD and controls but 
that there is a difference in the number of functional effector 
cells. Jensen (1985) showed that the target cell binding and 
lysis kinetics of effector cells from patients with AD were 
normal, using a single cell assay, however the number of active 
effector cells was found to be reduced, ie. NK cells bound 
normally to their targets and those that went on to lyse the 
target did so normally, however there was a reduction in the 
number that did go on to the lytic step. Jensens results 
therefore support the hypothesis that the defect in the effector 
cells is qualitative.
An alternative explanation of these results exists. That is, 
as a difference was found in the numbers of HNK-1**" cells and not 
Leu-llb**" between patients and controls it is possible that the 
effector cells are required to carry both markers in order to be 
fully functional, ie. to be HNK—1**" and Leu-llb**", This would 
suggest that the effector cells may be HNK—1 Leu—lib"*" in 
patients with AD and HNK-1**" Leu-llb^ in the controls. This 
explanation conflicts with the findings of Lanier et al. (1983) 
who found that effedtor cells with the Leu-11**" 7- (HNK-1 ) 
phenotype were more active than those with the Leu-11**" 7**^ 
phenotype. However, Lanier et al. (1983) used only three 
individuals, and without the benefit of double labelling
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although a larger population was studied, it is not possible to make 
a definite statment. From the available data, assuming Leu- 11b to be 
more specific than HNK-1, it is possible that NK effector cells from 
patients with AD express the Leu-11 marker without being able to 
perform the function due to either inhibition of the cellular response 
or immaturity of the effector cells. It would therefore appear that 
there are normal numbers of effector cells present, as defined by the 
Leu-llb monoclonal marker, but there,.is a reduction in the number of 
functional cells. Another possibilty for the observation of reduced 
NK activity in AD is that the effector cells have migrated to the skin 
Leung et al. (I982) have shown increased NK cell activity to autologous 
skin fibroblasts. It has been shown, however that the infiltrating 
cells are predominatly T helper cells and that NK cells are seen only 
occasionally (Leung et al. I98I: H,S, Lever, personal communication).
A possible cause of this NK effector cell dysfunction could be 
the presence of an inhibitory factor. Rogge and Hanifin (1976) 
observed that in severe cases of AD there was impaired lymphocyte 
transformation and neutrophil chemotactic responses, Hanifin et al, 
(1980) showed that this depression correlated with the disease 
state and suggested that it was due to a factor in the patient's 
plasma. Suppression of NK cell activity of normal controls has 
been observed following incubation of effector cells in media 
supplemented with sera from patients with systemic lupus 
erythematosus (Sibbitt, et al. 1983), or maternal, ie. newly 
delivered mothers, or neonatal sera (Barrett, et al. I982). These 
observations suggest that there may be an inhibitory substance 
present in the circulation of patients with AD that is responsible 
for the reduced NK cell activity. If an inhibitory factor is 
present in the serum of patients with AD it might be expected to
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reduce the UK cell activity of effector cells from control subjects 
conversely it may be possible to increase the activity of "atopic" 
cells by incubation in medium supplemented with normal serum.
However, from the results it would appear that there is no inhibitory 
factor specific for NK cells as there appears to be for chemotaxis, 
although a very slight increase in the NK cell activity of patient's 
effector cells incubated in medium supplemented with control serum 
was observed. Likewise, a similar very slight decrease in control 
NK cell activity was observed when the assay was carried out in 
medium supplemented with patient's serum. However, neither of 
these proved to be significant.
Longer incubation, l8 hours instead of 4-, failed to reveal 
the presence of an inhibitory substance in the serum of patients.
Also there was no enhancement of the slight increase seen in the 
NK cell activity of patients effector cells following a four hour 
assay in medium containing 10% control serum. Likewise there was 
no further decrease in control effector cell activity when 
assayed for l8 hours in medium containing 10% patient’s serum.
The longer incubation did, however, reinforce the earlier findings 
on the effect of 4 and l8 hour incubations on NK cell activity, 
ie. NK cell activity increases with longer incubations, both the 
patients and the controls, but the difference between them 
remains the same. The most interesting results were found with a 
standard 4 hour assay following an l8 hour preincubation of 
effector cells in the various supplemented media. The major 
difference observed was the marked increase in the NK cell 
activity of the cells that had been incubated in medium containing
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10% FCS seen in both patients and controls. This increase was 
most likely due to the recognised stimulatory effects of the FCS 
(Zielske and Golub 1976). The activity of patient's effector 
cells that had been incubated in 10% FCS rose to a level similar 
to that of control cells that had been incubated in 10% autologous 
serum. This finding suggests that the effector cells from patients 
with AD have the potential to reach the same level of activity as 
unstimulated control cells. Hanifin et al. (l980) observed 
that the decrease in neutrophil chemotaxis correlated with the 
severity of the disease, this would suggest that an inhibitory 
factor for chemotaxis is either absent during remission, or present 
only in very small amounts, and increases in concentration during 
episodes of flare. Although all the patients investigated had 
moderate to severe episodes of AD when studied,no inhibitory 
factor was observed with the three protocols employed, ie. the 
four hour assay, 1^ hour assay or the 18 hour preincubation 
followed by a four hour assay. This suggests that the low levels 
of NK cell activity in AD are not due to the presence of a 
specific inhibitor of NK cell function such as that postulated 
by Hanifin et al. (1980) for chemotaxis.
If the defect in NK cell function of patients with AD is not 
due to an inhibitory factor and not due to reduced numbers of 
effector cells it is possible that the treatment of the disease 
is the cause. The mainstay of treatment of AD is with topical 
steroids. It has been shown that systemic steroids can cause
101
depression of NK cell activity (Parillo and Fauci, 197&). The 
possibilty exists therefore that systemic absorption of topically 
applied steroids may cause the reduced levels of NK cell activity.
This hypothesis would explain the relationship of NK cell activity to 
clinical activity, as the disorder worsens so the patient will use 
more steroids. However, it does not explain the persistently low 
levels of NK cell activity that ate found in a few patients with 
inactive disease and little or no steroid use.
The effect of the application of topical steroid was investigated 
in a group of ten normal volunteers. NK cell activity was observed to 
falland reached statistical significance on day seven. A smaller 
reduction in NK cell activity was observed when the base alone was 
used, this reduction was not statistically different from the original 
base line values. In neither case, ie ointment or base, was the fall 
in NK cell activity as great as that seen in AD.
There are three possible reasons as to why the results are 
inconclusive. Firstly, although the steroid preparation used was 
strong, the period of application, seven nights, may not have 
been long enough. The NK cell activity of the group fell during 
the period of steroid'application and then started to recover. 
Statistical; significance was achieved on day seven, the last day 
of application of the steroid. It is possible that if the period 
of application was longer an even greater reduction in NK cell
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activity would have been seen. However, seven dâys was thought 
to be long enough, due to the side effects of steroid treatment. 
Secondly, it is likely that patients with active dermatitis 
absorb greater amounts of steroids than volunteers with an intact 
skin. Lastly, if the group that applied the base was larger, it is 
possible that the difference between that group and the group that 
used the steroid would have been larger and therefore significant.
The observation that RK cell activity correlated with the 
severity of the disorder and the observation of Hanifin et al. (198O) 
that the chemotactic response also correlated with the disease state 
may be explained by the use and effect of topical steroids.
Patients with active disease use greater amounts of stronger 
steroids than patients in remission which would cause greater inhibi­
tion of cellular function, with clinical improvement both the 
quantity and strength of steroid used decreases which would reduce 
the amount of suppression.
A further possibility for the reduced NK cell activity is the 
presence of pharmacological mediators. Stress is well recognised 
to be a trigger in AD, and some of the pharmacological mediators 
of stress were found to cause inhibition of the NK cell response 
of normal effector cells at pharmacological doses in vitro.
Adrenaline and noradrenaline caused a dose dependent inhibition 
of NK cell activity which was statistically significant at a 
concentration of 0,0005 mM for -adrenaline and 0.0002mM for
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noradrenaline. These mediators act via the adenyl cyclase 
receptor which catalyses the conversion of ATP to cAMP (Nimmo,
1984), ’ It is well documented that cAMP and its inducers such as
prostaglandins, histamine, theophylline etc. can cause inhibition 
of NK cell activity (Roder and Klein 1979î Katz et al. 1982:
Goto et al. 1983: Hall'et al, I983). It would therefore appear
that adrenaline and noradrenaline could mediate their effect via 
oAMP. The greatest levels of inhibition were found when these two 
agents were added at the start of the four hour assay. Conversely,
the lowest levels of inhibition were found following a four hour 
preincubation of effector cells with these agents. This suggests 
that the effect is short lived and that aHtlenaline, noradrenaline 
and the cAMP they induce are metabolised and that once removed 
thr- effector cells then start to return to normal. Katz et al.
(1982) also noted that, following the addition of cAMP inducers,
NK cell function was reduced but that this reduction only lasted 
two hours before returning to normal baseline levels. Although 
these results have shown that adrenaline and noradrelanine have a 
profound effect on NK cell activity in vitro at pharmacological 
doses, it does not necessarily follow that similar effects would 
occur under physiological conditions in vivo.
As topical betamethasone appeared to reduce NK cell activity 
in vivo, its effect in vitro was therefore examined. A very 
significant reduction in NK cell activity was observed when 
betamethesone was added to the assay. The reduction was shown
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to be doee dependent and was statistically significant at a 
concentrâticn of QOOOYmM, Betamethesone is thought to have its 
effect through binding to membrane phospholipids (Nimmo I984).
It ,,is therefore possible that a defect in target cell binding 
occurs, although the killing step is probably still intact as it 
has been shown that steroids do not inhibit ADCC (Parillo and 
Fauci 1978). Again, as with adrenaline and noradrenaline, the 
degree of inhibition is time dependent ie. the longer the 
betamethesone is in contact with the effector cells the less the 
resulting inhibition. Therefore betamethesone must be either 
metabolised or lost through membrane turnover. This in vitro 
finding also strengthens the hypothesis that topically applied 
steroids may cause a reduction in NK cell activity.
The effects of incubating effector cells with histamine was
also studied as histamine release is well recognised to be of
importance in related allergic conditions such as urticaria. It
was observed, following one hours preincubation, that there was
an increase in NK cell activity that was negatively doye
dependent ie, the lower the dose the greater the NK cell activity.
This conflicts with histamines reported ability to suppress NK
cell activity. It has been reported that histamine causes
inhibition of NK cell activity via the induction of cAMP (Katz
et al. 1982: Hall et al. 1983) This apparent contradiction may
be explained by the findings of Safko et al. (1981) who showed
“3that while the addition of histamine at concentrations of 10 M
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causes a 20C% rise in the level of cAMP that PBMC can produce, 
pretreatment of the cells with very low doses of histamine,
10""^M., caused a reduction in the amount of cAMP produced.
The concentrations of histamine used in this study were of the 
order ofCj,3xlO M. and lower, it is therefore likely that these 
lower concentrations of histamine were causing a reduction in 
the amount of cAMP being produced and therefore increasing the 
NK cell activity. However, the addition of the highest concen­
tration of histamine, 0,03 mM, at the start of the assay caused 
inhibition of the NK cell response. This suggests that the 
concentration used was enough to cause inhibition. In contrast, 
a four hour preincubation of effector cells with this concentration 
of histamine caused an increase in NK cell activity which was of a 
similar magnitude to that seen following one hours preincubation 
with histamine at the lowest concentration, Q,00003mM, This 
again suggests that the effect of histamine is short lived due to 
its being metabolised or to the loss of bound histamine through 
membrane turnover. As histamine concentration falls so the cAJ5P 
production falls with a resultant increase in NK cell activity.
The normal level of histamine in the blood is very low, approx­
imately lug/ml., which is approximately 10' times lower than the 
lowest concentration used in this experiment. It is tempting to 
suggest that at even lower concentrations histamine would have an 
even greater effect on NK cell function. However, in the light
of the very different effects histamine has at higher concentrations
—3 —3 —6ie 10 M. compared to those at lower concentrations eg. 10 to 10 M.,
106
it is impossible to predict its effect in vivo. The action of 
histamine is generally a local one and is short lived it is therefore 
unlikely that at physiological doses histamine would have any 
measurable effect cm circulating NK cells.
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CHAPTER ELEVEN-
CONCLUSIONS
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The results of this study have shown that the natural killer 
cell activity of PBMC from patients with atopic dermatitis is greatly 
reduced,■
A sequential study of NK cell activity in AD revealed a correlation 
"between disease severity and NK cell activity, suggesting that the 
reduction might "be an integral part of the disease process or an 
epiphenomenon related to the disease# i.e. Does the disease itself 
cause the reduction in NK cell activity or is there some other cause 
such as the treatment?.
If the disease is causing the reduction in NK cell activity then 
it may he through a reduction in effector cell numbers or by inhibition 
of effector cell function,
Fluorescent marker studies with two monoclonal antibodies (HNK-1 
and Leu-llb) against NK cell surface markers gave different results,for 
reasons given elsewhere it was assumed that the results obtained with 
Leu-llb were the more correct. These suggested that the kinetics of the 
effector cell response were different for patients and controls, indeed 
it has been shown, using a single cell assay, that there are normal 
numbers of effector cells present in the circulation of patients with 
AD but that only a percentage of them are fully functional (jensen,
1985).
The possibilty that the reduction in NK cell activity was due to 
the presence of an inhibitory factor was therefore investigated. No 
inhibitory factor, specific for NK cell function, was detected. This 
inferes that the cause of the reduction is due to something other than 
the disease.
The last point to be investigated therefore was whether the 
treatment of the disorder was responsible for the reduction in NK cell 
activity.
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Topical steroids, which form the mainstay of treatment in AD, 
were found to cause a reduction in the NK cell activity of normal subjects. 
The observed decrease in NK cell activity was less than that seen in 
patients with AD, Because of the effect topical betamethasone had on 
NK cell activity in vivo the in' vitro effect was also examined, A 
much greater reduction in NK cell activity was observed in vitro than 
that found in vivo, these results support the hypothesis that steroids 
applied topically may cause a reduction in NK cell activity.
Pharmacological doses of adrenaline and noradrenaline were also 
found to cause a significant reduction in NK cell activity in vitro. 
However, the results suggested that,at physiological concentrations, 
there would be no detectable effect on NK cell activity,
Preincubation: of effector cells with histamine at various 
concentrations was found to cause a alight enhancement of NK cell 
activity. In contrast, if histamine was added at the start of an 
assay an inhibition of the NK cell response was observed. Histamine 
is only present in very small concentrations, less than 1ng/ml, in 
the blood of normal subjects, although elevated levels have been 
found in individuals with AD, up to 3ng/ml. (Ring, et al, 1979). 
higher concentrations of histamine have been reported in the skin 
of patients with AD,l6ug/g of skin compared with 9.2ug/g of skin 
for controls. (Johnson, et al, I960), The levels of histamine in vivo 
are lower than those studied in vitro. In addition as the main 
action of histamine is local and probably short lived, it is unlikely 
that histamine is envolved in the reduced NK cell activity in AD,
The results of this study show that NK cell activity is indeed 
reduced in AD, They do not show if there is a pathological mechanism
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in AD which causes the primary reduction in NK cell activity hut 
rather they suggest that the reduction is an epiphenomenon which may 
be related to the treatment of the disease in the following hypothetical 
way.
When:a patient with AD relapses, via an antigenic trigger or 
through stress or a combination of both there is an increase in 
inflammation, monocytes may aggregate at the site of inflammation and 
release products such as prostaglandins which could inhibit NK cell 
activity. The patient will then increase the amount and strength of 
topical steroids to control the flare, these may be absorbed in high 
enough concentrations to cause further inhibition of NK cell activity. 
With improvement less steroids are used topically which may result in 
less inhibition of NK cell activity. The consistently low levels of 
activity that are seen may be due to the chronic relapsing nature of
the disorder, ie. The effector cells do not have enough time to
fully recover their function between episodes of flare. Mice treated
with steroids have been found to take from six to eight weeks to
regain their baseline levels of NK cell activity. It has also been 
found in humans that it takes up to $ 6  hours for NK cell activity to 
return to normal following a single dose of 8mg of hydrocortisone 
taken orally (Seaman, et al, 1978; Parillo and Fauci, 1978), The 
results of patient MN would appear to support this contention.
The disease, treatment, recovery cycle may also explain the 
observation of normal numbers of effector cells but with reduced 
function. As AD is a chronic disorder so the treatment of the 
disorder is also long term. It may be postulated that the 
continued use of g_uite mild steroids over a long period of time
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may cause chronic inhibition of NK cell function (it has been shown 
in this study that even very low concentrations of steroids may 
inhibit NK cell function in vitro). The dose of steroid may not be enough 
to cause lymphopenia but may be enough to maintain the inhibition 
of the NK response. It is possible that once the level of NK cell activity 
is reduced it may only require very small doses to maintain the reduced 
level of activity. Figure 23 illustrates the disease, treatment 
recovery cycle.
The role of steroids in A3) therefore needs more closer examination. 
This would require access to patients before they ever use steroids, 
finding such a group of patients would be very difficult as patients 
usually have been prescribed steroids by their general practitioner 
before they see a dermatologist. One solution would be to test the 
NK cell activity of mononuclear cells from cord blood from infants 
whose mothers or fathers have AD and compare this with cord blood 
from infants b o m  to non atopic parents. Then follow the progress of 
these children for one year (AD usually develops in the first year 
of life). If the child develops AD it would then be possible to 
retest the NK cell activity before starting treatment. This would 
answer' several questions, 1) is NK cell activity already reduced 
in these individuals ?, 2)does development of the disease lead to 
reduced levels of 3) or is the treatment the cause of the
reduction in NK cell activity.
In retrospect it may have been useful to look further at the 
role of macrophages in AD. Removal of phagocytic cells by carbonyl 
iron ingestion resulted in a significant increase in the NK cell 
activity of patients with AD, This treatment, while being effective
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Figure 23.
Antigenic trigger Stress I
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Monocytes and ^  
Monocyte products
Steroid treatm ent
Reduced NK cell activity
Steroids control disease
1
Recovery -------------------► Stress |
I
Reduce steroid application
NK cell activity increases
Possible mechanisms involved in reduced NK cell activity in 
patients with AD*
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in removing phagocytic oells^  is not 100% effective. It would he of 
interest therefore to examine what effect indomethacin treatment of 
effector cells would have on NK cell activity. It is possible that 
a greater increase in NK cell activity could be achieved if 
macrophage function was completely abrogated, rather than trying to 
reduce the numbers present. This would reveal just how much of a 
role macrophages had in AD, if any?.
A further study that may have proved useful would have been to 
examine ADCC in these patients. It is known that NK cells can also 
function in ADCC and that ADCC is unaffected by steroids, therefore 
if ADCC were normal in these patients then it may be said with increased 
confidence that topical steroid treatment was the cause of the reduced 
NK cell activity in AD, although the role of steroids would require 
further investigation as suggested above.
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